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cell line NTera2, we show that wild-type p53 is mono-methylated at Lysine 370 and Lysine 382. These
post-translational modifications contribute to the compromised tumor suppressive activity of p53 despite
a high level of wild-type protein in NTera2 cells. This study provides evidence for an epigenetic
mechanism that cancer cells can exploit to inactivate p53 wild-type function. The paradigm provides
insight into understanding the modes of p53 regulation, and can likely be applied to other cancer types
with wild-type p53 proteins. On the other hand, cancers with TP53 mutations are mostly found to contain
missense substitutions of the TP53 gene, resulting in expression of full length, but mutant forms of p53
that confer tumor-promoting “gain-of-function” (GOF) to cancer. In the second section of my dissertation, I
have investigated the mechanism of this GOF property by examining genome-wide p53 binding profiles in
multiple cancer cell lines bearing p53 mutations. This reveals an epigenetic mechanism underlying
mutant p53 GOF. Various GOF p53 mutants bind to and upregulate genes including MLL1, MLL2, and
MOZ, leading to genome-wide changes of histone modifications. These studies also demonstrate a
critical functional role of the MLL pathway in mediating mutant p53 GOF cancer phenotypes, and that
genetic or pharmacological perturbation of MLL function can achieve specific inhibition of GOF p53 cell
proliferation. Overall, studies described in this dissertation demonstrate the crosstalk between p53
signaling and chromatin regulatory pathways, contribute to our knowledge of p53 cancer biology with
respect to epigenetic regulation, and in the long term suggest new therapeutic opportunities in targeting
cancers according to their p53 mutational status.
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ABSTRACT

INTERPLAY BETWEEN p53 AND EPIGENETIC PATHWAYS IN CANCER
Jiajun Zhu
Thesis advisor: Shelley L. Berger, Ph.D.
The human TP53 gene encodes the most potent tumor suppressor protein p53. More than half of
all human cancers contain mutations in the TP53 gene, while the majority of the remaining cases
involve other mechanisms to inactivate wild-type p53 function. In the first part of my dissertation
research, I have explored the mechanism of suppressed wild-type p53 activity in teratocarcinoma.
In the teratocarcinoma cell line NTera2, we show that wild-type p53 is mono-methylated at
Lysine 370 and Lysine 382. These post-translational modifications contribute to the compromised
tumor suppressive activity of p53 despite a high level of wild-type protein in NTera2 cells. This
study provides evidence for an epigenetic mechanism that cancer cells can exploit to inactivate
p53 wild-type function. The paradigm provides insight into understanding the modes of p53
regulation, and can likely be applied to other cancer types with wild-type p53 proteins. On the
other hand, cancers with TP53 mutations are mostly found to contain missense substitutions of
the TP53 gene, resulting in expression of full length, but mutant forms of p53 that confer tumorpromoting “gain-of-function” (GOF) to cancer. In the second section of my dissertation, I have
investigated the mechanism of this GOF property by examining genome-wide p53 binding
profiles in multiple cancer cell lines bearing p53 mutations. This reveals an epigenetic mechanism
underlying mutant p53 GOF. Various GOF p53 mutants bind to and upregulate genes including
MLL1, MLL2, and MOZ, leading to genome-wide changes of histone modifications. These studies
v

also demonstrate a critical functional role of the MLL pathway in mediating mutant p53 GOF
cancer phenotypes, and that genetic or pharmacological perturbation of MLL function can
achieve specific inhibition of GOF p53 cell proliferation. Overall, studies described in this
dissertation demonstrate the crosstalk between p53 signaling and chromatin regulatory pathways,
contribute to our knowledge of p53 cancer biology with respect to epigenetic regulation, and in
the long term suggest new therapeutic opportunities in targeting cancers according to their p53
mutational status.
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CHAPTER 1
General introduction

This chapter is background introduction to the dissertation work. It provides an overview of the
p53 tumor suppressor, “gain-of-function” p53 mutations, and epigenetic regulatory pathways.
Our current knowledge of their roles in human cancer is the primary focus of this chapter, with
particular emphasis on aspects directly related to this dissertation.
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1.1

Wild-type p53 is a potent tumor suppressor

1.1a

Discovery of p53 – from tumor antigen to tumor suppressor

In 1979, Lane and Crawford (Lane and Crawford, 1979) and Linzer and Levine (Linzer and
Levine, 1979) reported that the SV40 large tumor antigen was bound to a 53 kD (kilodalton)
human cellular protein which thereby acquired the name p53. This observation and others
following had soon become the first explanation as to how SV40 tumor antigen transform cells,
and p53 was therefore initially recognized as an oncogenic protein (DeLeo et al., 1979)
In the following years, many groups simultaneously worked on cloning the p53 gene, and had
obtained multiple clones independently. Among these were the Oren’s clone (Moshe Oren) from
a mouse liver genomic library (Bienz et al., 1984; Oren and Levine, 1983) and the Pennica’s
clone (Dianne Pennica) from mouse F9 teratocarcinoma cells (Pennica et al., 1984), for example.
People were keen to test if p53 was truly an oncogene that could transform cells, as suggested by
its discovery as a tumor antigen. However, results were contradictory depending on which
specific p53 clone was used to perform the transformation experiments (Eliyahu et al., 1984;
Jenkins et al., 1984; Parada et al., 1984).
Finally, after almost ten years’ effort from the initial discovery, the field eventually came to
appreciate that p53, in its wild-type form, acts as an anti-oncogenic or tumor suppressor protein
(Baker et al., 1989; Finlay et al., 1989; Finlay et al., 1988), whereas other clones of p53 that only
differ by one amino acid from the wild-type form, when overexpressed, could act as an oncogenic
protein (Ben David et al., 1988; Hinds et al., 1989; Munroe et al., 1988). Interestingly, the Oren’s
clone, which was based on the mouse liver genomic library (Bienz et al., 1984) turned out to be a
-2-

mutant form of p53, whereas the Pennica’s clone derived from mouse F9 teratocarcinoma cells
(Pennica et al., 1984) is wild-type. In fact, many transformed cell lines in culture contain a
diverse set of mutant p53 but most teratocarcinoma cell lines or tumors contain wild-type p53
protein (Lutzker and Levine, 1996).
The first ten years of p53 discovery, from its original identification as a tumor antigen until
finally recognized as a tumor suppressor, although dramatic and torturous, has demonstrated
typical progress of scientific advance. More important, these findings opened up whole new
avenues of investigations of p53 biology and our understanding of human cancer. The debate
around p53 being oncogenic or tumor suppressive in the context of teratocarcinoma and other
cancers also provided direct rationale for studies discussed in this dissertation, as detailed below.

1.1b

Wild-type p53 functions as a transcription factor

The realization of p53’s function as a tumor suppressor has prompted the search for its
mechanism. Soon people came to recognize p53 as a transcription factor along with the
identification of its consensus DNA binding motif (el-Deiry et al., 1992; Funk et al., 1992) as 5′RRRCWWGYYY-3′ (R = guanine or adenine, G or A; W = thymine or adenine, T or A; Y =
cytosine or thymine, C or T). Studies have also revealed structural features of the p53 protein.
p53 is divided into several domains (Figure 1.1): an amino-terminus containing two tandem
transcriptional activation regions (residues 1-42 and residues 43-92) (Brady et al., 2011; Candau
et al., 1997; Unger et al., 1992); a sequence-specific core DNA-binding domain (residues 101300) (Bargonetti et al., 1993; Halazonetis and Kandil, 1993; Pavletich et al., 1993; Wang et al.,
1993); a tetramerization domain required for oligomerization of the proteins (residues 326-356)
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(Pavletich et al., 1993; Sturzbecher et al., 1992; Wang et al., 1993); and a carboxyl-terminus
regulatory region (residues 364-393) (Wang et al., 1993).
These findings pointed to p53’s major cellular role as a transcriptional factor. Over decades,
people have identified many transcriptional target genes of p53, among which are: p21 (also
known as CDKN1A) (el-Deiry et al., 1993); MDM2 (Momand et al., 1992; Wu et al., 1993);
PUMA (also known as BBC3) (Nakano and Vousden, 2001); BAX (Miyashita and Reed, 1995);
GADD45A (Kastan et al., 1992); and many others. Collectively, they have revealed downstream
pathways that p53 dictates (Figure 1.2), including DNA damage checkpoint (Kastan et al., 1992),
cell cycle arrest (el-Deiry et al., 1993), senescence (Lin et al., 1998; Serrano et al., 1997),
apoptosis (Miyashita and Reed, 1995; Nakano and Vousden, 2001), metabolism (Vousden and
Ryan, 2009), differentiation (Almog and Rotter, 1997; Stiewe, 2007) and most recently, irondependent ferroptosis (Jiang et al., 2015).
These pathways overall contribute to the tumor suppressive function of p53, yet how p53
mechanistically distinguishes among these choices is still largely undetermined, as many
outcomes are mutually exclusive from each other. One possible explanation is that p53 utilizes
chromatin environmental information to instruct the activation of context-specific genes. This is
supported by a number of studies showing that co-factors or local chromatin features can bias
p53’s target gene activation, particularly the decisions between cell cycle arrest and apoptosis
pathways (Desantis et al., 2015; Espinosa and Emerson, 2001; Gomes and Espinosa, 2010;
Samuels-Lev et al., 2001). Post-translational modifications (PTMs) have also been shown as a
mechanism to modulate p53 target selection (Smeenk et al., 2011; Tang et al., 2006), in addition
to serving as integrators of cellular stress signals to control p53 activity, as detailed below and in
Chapter 3.

-4-

1.2

Hotspot p53 mutations and the “gain-of-function” (GOF) hypothesis

1.2a

Formulation of the GOF hypothesis

Soon after the discovery of p53, it became clear that p53 is the most frequently mutated gene in
all human cancers. Typically one allele of p53 contains a missense mutation while the other allele
is rearranged or deleted – a process known as “loss of heterozygosity”. It results in expression of
a mutant form of p53 in the absence of wild-type protein. This idea is also supported by findings
from the Li-Fraumeni Syndrome (LFS) families, where patients are born with p53 germline
mutations and are highly susceptible to developing cancers later in their lives (Malkin et al.,
1990). These early observations and others have collectively led to the recognition that during
tumor progression, cancer cells are selecting for p53 missense alterations, or in other words, p53
missense mutations may confer growth advantage to tumors (Levine et al., 1991; Prives and
Manfredi, 1993).
More detailed analyses of specific animo acid residues that are most frequently substituted
uncovered four regions (residues 117-142, 171-181, 234-258, and 270-286) in the DNA-binding
domain of p53 protein wherein mutations primarily occur. Accumulating clinical evidence now
has revealed several hotspot residues of mutation, including R175, R245, R248, R249, R273, and
R282 (Freed-Pastor and Prives, 2012; Olivier et al., 2010; Soussi et al., 1990). Structural studies
provide explanations for the prevalence of mutational clusters. These regions provide either direct
DNA contacts, or structural scaffolding supports for DNA binding (Cho et al., 1994). Notably,
structural and biochemical analyses also suggest that mutations in certain residues or regions
could alter the p53 protein conformation, and therefore may provide the possibility for mutant

-5-

p53 novel functions beyond loss of wild-type direct DNA-contact-based transcription (Cho et al.,
1994).
While mutant p53 could exert both “dominant-negative” and “gain-of-function” effects, the latter
is supported by the initial mis-recognition of p53 (mutant forms) as an oncogene, as well as some
early findings showing that introducing mutant p53 into an otherwise p53 deficient background
enhanced the tumorigenic phenotype (Dittmer et al., 1993; Wolf et al., 1984). Later on with the
advent of mouse genetics, mutant p53 knock-in mice were generated, providing direct
demonstration of the GOF hypothesis. Specifically, with the knock-in of p53 R172H or p53
R270H (equivalent to human R175H and R273H, respectively) into the endogenous p53 gene
loci, mice develop different spectra of cancers with higher metastatic capacity compared to the
p53 knock-out counterparts. Further, ex vivo mouse embryonic fibroblasts (MEFs) from these
knock-in mice grow more rapidly than the MEFs from the knock-out mice (Lang et al., 2004;
Olive et al., 2004). Questions remain, including whether different hotspot mutations of p53 share
common GOF mechanisms while retaining distinct mutant-specific functions. The complexity is
further supported by evidence that different tissues have different preferences for p53 mutations,
and that different mutant p53 knock-in mice seem to have different extents of “gain-of-function”
phenotypes (Levine et al., 1991; Xu et al., 2014; Yoshikawa et al., 2010). Some of these points
will be revisited and further detailed in Chapter 4.

1.2b

Mechanisms and targets of GOF p53 mutants

The tumorigenic advantage of mutant p53 over the simple loss of wild-type activity has now been
tested by numerous experiments, providing insights into the downstream targets mediating “gainof-function”. For example, GOF p53 can increase chemotherapy resistance. In p53-null H1299
-6-

lung adenocarcinoma cells, introduction of certain p53 mutants can lead to cells becoming more
resistant to etoposide or cisplatin treatment (Blandino et al., 1999). Mutant p53 also enhances
resistance to drugs such as doxorubicin or cisplatin in M1/2 myeloid cells by interfering with
apoptosis pathways (Li et al., 1998). Moreover, as shown in Li-Fraumeni Syndrome fibroblasts,
mutant p53 transcriptionally activates TDP2, a 5’-tyrosyl DNA phosphodiesterase involved in
DNA damage repair, to promote etoposide resistance (Do et al., 2012). GOF mutant p53 also
contributes to elevated metastasis and invasiveness. For example, acquisition of mutant p53 in
p53-negative background results in increased metastatic potential and tissue invasiveness in
cervical cancer and lymphoblastic leukemia (Crook and Vousden, 1992; Hsiao et al., 1994). In
mouse models of pancreatic ductal adenocarcinomas following an initiating activating mutation
in KRAS, mutant p53, as compared with genetic loss of p53, specifically promotes metastasis
(Morton et al., 2010).
Along with these and many other phenotypic observations, mechanisms of mutant p53 “gain-offunction” have also started to emerge. One set of evidence points to mutant p53 functioning to
abrogate the tumor-suppressive activities of p53 family members p63 and p73 (Figure 1.3A). A
number of mutant p53 proteins bind to and interfere with the function of multiple isoforms of p63
(p63 α and -γ; ΔNp63 α and -γ) and p73 (p73 α, -β, -γ, -δ), thereby blocking p63 or p73 induced
apoptosis. The efficiency of mutant p53 binding to p63 and p73 correlates with the inhibition of
p63 and p73 function (Gaiddon et al., 2001; Marin et al., 2000; Strano et al., 2000). In a mouse
model of pancreatic cancer, a highly metastatic disease that frequently displays p53 mutations,
mutant p53 inhibits p73/NF-Y complex which otherwise represses the expression of platelet
derived growth factor receptor β (PDGFRβ), a necessary and sufficient factor to maintain the
prometastatic phenotype (Weissmueller et al., 2014). This paradigm can also crosstalk with other
signaling pathways. For instance, mutant p53 and p63 protein complex can serve as an essential
-7-

platform to further form a ternary complex with Smad proteins. Through this mechanism, mutant
p53 empowers the switch of TGFβ signaling from early stage tumor suppressive to become
prometastatic factors in advanced cancers (Adorno et al., 2009).
In addition to the inhibitory role of mutant p53 to p63/p73 functions, another large set of findings
support a more direct “gain-of-function” role of mutant p53, where an intact transactivation
domain of mutant p53 is required. For example, mutant p53 is recruited by the SREBP
transcription factors to activate the mevalonate pathway in breast cancer cells, and therefore
disrupts the three-dimensional tissue architecture and promotes tumorigenesis (Freed-Pastor et al.,
2012). Mutant p53 can also physically and functionally interact with vitamin D receptor (VDR)
and modulate VDR-regulated genes – augmenting expression of some genes while relieving the
repression of others, and overall contributing to an anti-apoptotic phenotype (Stambolsky et al.,
2010). Mutant p53 can also bind ETS family proteins and activate genes contributing to cancer
cell migration and invasion, as well as drug resistance (Do et al., 2012; Xiong et al., 2014). In
addition, “gain-of-function” of mutant p53 has been attributed to association with promoter
regions of certain micro RNAs and hence to activate these tumorigenic non-coding RNAs. It is
not yet clear how mutant p53 binds to these genomic regions encoding the micro RNAs, but it is
likely through interaction with other cofactors (Donzelli et al., 2014; Masciarelli et al., 2014;
Wang et al., 2013).
Collectively, these studies provide evidence for alternative mechanisms where mutant p53 can be
directed, through interaction with other transcription factors, to novel genes, and functionally
activate pro-tumorigenesis pathways (Figure 1.4B). In fact, the unleashed ability of mutant p53 to
associate with novel regulatory factors has been suggested from the structural study of wild-type
p53, as mentioned above (Cho et al., 1994). Biochemical assays have also started to reveal critical
-8-

interaction mechanisms of mutant p53 with different partners (Do et al., 2012; Zhao et al., 2015).
Uncovering these binding details offers potent therapeutic opportunities to specifically target
tumors with “gain-of-function” mutant p53. Some of these points will again be revisited and
further detailed in Chapter 4 and Chapter 5.
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1.3

Chromatin pathways and epigenetics

It has now been well established that genomic and chromatin features play key, if not decisive
roles on gene expression outcomes of associated transcription factors (Kouzarides, 2002, 2007).
The potent transcription factor p53 is subject to tight modulation by local epigenetic
characteristics. On the other hand, the effect of transcription factors can also manifest through
broad epigenetic changes. This section discusses basics of chromatin pathways, with particular
emphasis on topics directly related to later chapters in this dissertation.

1.3a

Histone modifications and gene transcription

In all eukaryotic cells, the genetic information DNA is highly compacted into the chromatin
structure by histones and nonhistone proteins. Nucleosomes are the basic repeating unit of
chromatin, each consisting of 146 base pairs (bp) of DNA, or roughly two helical turns of DNA
wrapping around a core histone protein octamer – an H3-H4 tetramer and two H2A-H2B dimers
(Luger et al., 1997). These histones are small basic proteins with core globular domains, and
relatively unstructured amino-terminal tails that are subject to heavy post-translational
modifications.
Covalent post-translational modifications on histones represent an important component of
potentially heritable, but reversible changes in gene expression that occur without alterations in
DNA sequences (Jenuwein and Allis, 2001). Elegant genetic experiments in Saccharomyces
cerevisiae and Drosophila melanogaster provided some of the earliest findings of covalent
histone modifications. These studies were largely based on the observation known as positioneffect variegation (PEV), which indicates that the epigenetic “on-and-off” transcriptional states
are greatly dependent on the position of a gene within euchromatic (accessible) or
- 10 -

heterochromatic (inaccessible) chromatin environment. Genetic screens in flies identified a class
of genes that suppress the variegation phenomenon, or the Su(var) group. This group of genes
turns out to be members of the histone deacetylases (HDACs), histone methyl-transferases,
protein phosphatases, and chromatin associated components such as the heterochromatin protein
HP1. Deletion of genes in this group rescues the variegation phenotype (Eissenberg et al., 1990;
Wallrath, 1998). On the other hand, these genetic screens also identified another class of PEV
modifiers that enhance the variegation phenomenon, or the E(var) group, several members of
which turn out to be components of adenosine triphosphate (ATP) – dependent chromatin
remodeling complexes (Kal et al., 2000; Tsukiyama and Wu, 1997), the other family of chromatin
modifiers in addition to covalent histone post-translational modifications. Further extensions of
these discoveries in Su(var) and E(var) revealed critical and conserved structural and catalytic
domains including the bromo-, chromo- and SET domains. These domains are universally shared
by other chromatin regulators, for example, SNF2, Su(var)3-9, and the Polycomb and trithorax
groups (Dhalluin et al., 1999; Tschiersch et al., 1994; van Lohuizen, 1999), and have therefore
largely expanded our understanding of chromatin pathways.
Until now, there are at least eight different classes of covalent modifications identified, involving
at least 60 distinct modification sites on histones. These modifications include: lysine acetylation,
lysine and arginine methylation, serine and threonine phosphorylation, lysine ubiquitylation,
lysine sumoylation, glutamate poly-ADP ribosylation, arginine deamination and proline
isomerization. All of these modifications are functionally related to gene transcription, in addition
to other biological processes such as DNA repair, replication and chromatin condensation
(Bannister and Kouzarides, 2011; Kouzarides, 2007; Tessarz and Kouzarides, 2014). The
chemical modifications and vast array of modifiable sites in numerous canonical and variant
histones give chromatin enormous potential for functional responses. Further, the dynamic feature
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of most of the modifications brings in extra complexity as well as more refined spatial and
temporal gene regulation.
There are two categories of well-characterized mechanisms for the influence of histone
modifications on gene regulation and other biological processes. The first mechanism involves
alteration of intra- and internucleosomal histone/DNA contacts via steric or charge changes (also
known as “cis” mechanism); and the second mechanism involves recruitment or occlusion of
non-histone proteins, or “readers” of specific modifications (also known as “trans” mechanism).
The “trans” mechanism seems to be more universal to most of the chromatin associated
biological processes (Wang et al., 2007).
Lysine acetylation and methylation are best studied for their roles in gene transcriptional
regulation. Acetylation is almost invariably associated with transcription activation (Sterner and
Berger, 2000), whereas the output of lysine methylation can be either activation or repression to
transcription (Bannister and Kouzarides, 2005). Methylation on histone H3 Lysine 4, Lysine 36
and Lysine 79 (H3K4, H3K36 and H3K79, respectively) has generally been implicated in
activation of gene transcription. For example, H3K4 tri-methylation (H3K4me3) localizes to the
promoter region of active genes and is associated with the initiated form of RNA polymerase II
(Pol II, phosphorylated at serine 5). H3K36 tri-methylation (H3K36me3) is enriched in the gene
body and usually associates with the elongating form of RNA Pol II (phosphorylated at serine 2).
On the other hand, methylation on histone H3 Lysine 9, Lysine 27 (H9K9, H3K27, respectively)
and histone H4 Lysine 20 (H4K20) is linked to transcription repression. For example, H3K9 trimethylation (H3K9me3) is involved in forming silent heterochromatin and recruiting HP1 to
promoter regions of repressed genes. These histone modifications and the associated chromatin
factors cooperate with transcription factors to orchestrate gene expression.
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1.3b

Chromatin pathways and cancer – example of the MLL1 gene rearrangement

in leukemia
In addition to genetic alterations, epigenetic aberrations contribute to the initiation and
progression of human cancers (Wang et al., 2007).This is certainly not surprising, given the
global impact of chromatin pathways on gene transcription. In this section, the example of
H3K4me3 and the mixed lineage leukemia (MLL1, also known as MLL or KMT2A) gene
rearrangement is illustrated in the context of human leukemia. This discussion is also related to
content in Chapter 4.
The MLL1 gene was first identified because of its recurrent translocations in human leukemia,
accounting for about 80% of infant leukemia and 5-10% of adult acute myeloid leukemia (AML)
or lymphoid leukemia (Biondi et al., 2000; Huret et al., 2001). Later on, MLL1 was found to be
the gene encoding for a methyltransferase specific for H3K4 methylation (Milne et al., 2002;
Nakamura et al., 2002). The gene product MLL1 normally resides and functions in a complex
termed the COMPASS (complex associated with set1), together with other core complex
components including WDR5, RBBP5 and ASL2, as well as other associated factors such as
menin (also known as MEN1) (Figure 1.4). In human, there are six members of the COMPASS
complex family, each with a distinct core enzyme and variable associated components. The
proper assembly of the MLL1 COMPASS complex has been shown to be essential for the
efficient enzymatic activity of MLL1 as a H3K4 methyltransferase (Shilatifard, 2012).
There are two major mechanisms characterized for MLL1 mediated leukemia. The first one
involves the partial tandem duplication of MLL1 (MLL-PTD), which is the most prevalent form of
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MLL1 rearrangement in AML (Hess, 2004; Krivtsov and Armstrong, 2007; Shih et al., 2006).
The duplicated region contains the in-frame sequence of MLL1 exon 4 to 11. Even though this is
not a direct duplication of the MLL1 enzymatic SET domain (which resides towards the
carboxyl-terminus of MLL1 protein), a mouse model has demonstrated that MLL-PTD facilitates
H3K4me3, as well as H3 and H4 acetylation within the Hox gene clusters – major MLL1 targets
in normal hematopoietic development and aberrantly activated in leukemia. The enhancement of
acetylation is possibly due to increased recruitment of the acetyltransferases CBP and p300
(Dorrance et al., 2006).
The second class of MLL1 gene rearrangement are MLL1 fusions, where a part of MLL1 gene is
translocated and aberrantly fused with other partner genes. At least 50 different MLL1 fusion
partners have been identified in leukemia, of which the fusions with the nuclear proteins AF4,
AF9, AF10, ENL and ELL account for most cases. These translocation fusions usually lose the
carboxyl-terminal SET domain of MLL1, however, novel transactivation activity is acquired
through partnering with fusion components to reinsure, or even further enhance the expression of
Hox genes (Krivtsov and Armstrong, 2007). For example, a subset of fusion proteins, including
AF9, AF10 and ENL, directly or indirectly facilitate the recruitment of the DOT1L
methyltransferase and enhance H3K79me3 over Hox genes (Erfurth et al., 2004; Okada et al.,
2005; Zeisig et al., 2005). In addition, the MLL1-EEN fusion is shown to recruit the histone
arginine methyltransferase (PRMT1) to MLL1 target genes (Cheung et al., 2007). These and
other lines of evidence suggest that the loss of H3K4me3 catalyzing ability in cases of MLL1
fusions is in part compensated by other histone modification mechanisms, with further perturbed
local transcriptional control, to sustain activation of Hox clusters and other genes. Of course these
translocation fusion partners also assist in assembling additional transcription machineries such as
the “super elongation complex” family, contributing to dire tumorigenesis (Luo et al., 2012).
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The perturbation of histone modifications and chromatin pathways in cancer certainly goes
beyond leukemia and the MLL1 regulation. Various genetic and signaling alterations in multiple
cancer types have evolved to co-opt chromatin pathways in cancer initiation and progression. As
a result, targeting key components in the pathways have emerged as effective epigenetic
therapeutics in treating cancer.

1.3c

Post-translational modifications on p53

Post-translational modifications can also occur on non-histone proteins, and the first characterized
and best studied such protein is p53. As mentioned above, p53 contains a central DNA binding
domain as well as relatively unstructured amino-terminal and carboxyl-terminal regions. This
very much resembles the unstructured histone tails. Indeed, both the amino-terminus and the
carboxyl-terminus are subject to heavy post-translational modifications. There have been more
than 50 distinct modifications discovered on p53, including phosphorylation, ubiquitination,
neddylation, sumolation, acetylation, and methylation, and, again, the majority of them occur at
the amino- or carboxyl-terminal end (Meek and Anderson, 2009). Phosphorylation and
ubiquitination will be briefly introduced below, while more details will be discussed below
regarding acetylation and methylation, as they are more relevant to content in Chapter 3.
The p53 protein contains an array of serine and threonine phosphorylation sites that are mostly
concentrated within the amino-terminal transactivation domain (Dai and Gu, 2010). The majority
of these sites are rapidly phosphorylated following cellular stress such as DNA damage to help
stabilize p53, to recruit coactivators and to enhance transcription activity (Matsumoto et al., 2006;
Toledo and Wahl, 2006). On the other hand, polyubiquitination primarily targets p53 for
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proteasomal degradation. MDM2 is a canonical target of p53, the gene product of which is a
pivotal E3 ubiquitin ligase and negative regulator of p53. MDM2 can polyubiquitinate six lysine
residues within the carboxyl-terminal regulatory domain of p53. Upon cellular stress, the
stabilization of p53 is largely mediated through its dissociation from MDM2 by serine 15
phosphorylation (Shieh et al., 1997).
In addition to ubiquitination, the lysine residues in the p53 carboxyl-terminus can be alternatively
acetylated or methylated, resulting in drastically different outcomes. A total of nine acetylation
sites have been discovered on p53 (Dai and Gu, 2010). Six lysine residues (K370, K372, K373,
K381, K382 and K386) in the carboxyl-terminal region are acetylated mainly by CBP/p300
(Kruse and Gu, 2008). Acetylation on K320 in the tetramerization domain is catalyzed by PCAF
(p300/CBP-associated factor) (Liu et al., 1999). Two additional acetylation sites, K120
(acetylated by TIP60/hMOF) and K164 (acetylated by CBP/p300) are in the DNA binding
domain (Sykes et al., 2006; Tang et al., 2006; Tang et al., 2008). Similar to acetylation on histone
tails, p53 acetylation generally serves as a mechanism to activate p53 function, with slight
differences between different residues (Dai and Gu, 2010). For example, p53 K120 acetylation is
necessary for the activation of genes mediating apoptosis but not genes activating the cell cycle
arrest pathway (Sykes et al., 2006; Tang et al., 2006). In contrast, K320 acetylation favors cell
survival by promoting p21 activation while negatively regulating apoptosis (Chao et al., 2006;
Knights et al., 2006).
Methylation of p53 occurs on arginines or lysines. PRMT5 (protein arginine N-methyltransferase
5) can target R333, R335 and R337, therefore affecting the target gene choice of p53 (Jansson et
al., 2008). Lysine methylation has been more well characterized than arginine methylation on
p53. The functional outcomes can be either activation or repression (Berger, 2010; Dai and Gu,
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2010). Mono-methylation at K370 (K370me1, catalyzed by Smyd2, also known as KMT3C) and
mono-methylation at K382 (K382me1, catalyzed by Pr-Set7, also known as SETD8 or KMT5A)
are repressive to p53 transcriptional activity (Huang et al., 2006; Shi et al., 2007); whereas K372
mono-methylation (K372me1, catalyzed by SET7/9, also known as KMT7) activates p53
(Chuikov et al., 2004). Di-methylation at K373 (K373me2) by G9A and GLP (also known as
KMT1C and KMT1D, respectively) negatively regulates p53 (Huang et al., 2010), whereas K370
di-methylation (K370me2), recently found to be catalyzed by SETDB1 (Fei et al., 2015), was
shown to promote p53 function upon DNA damage by facilitating the association with the coactivator 53BP1 (Huang et al., 2007).
Post-translational modifications also occur on mutant p53, which may have similar functions as
they do on wild-type p53. However, more precise mechanistic details remain to be further studied
(Nguyen et al., 2014).
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1.4

Genome-wide binding of p53

1.4a

Genome-wide binding of wild-type p53

To date, there have been a number of studies carried out to assess genome-wide binding
properties of p53, mostly with chromatin immunoprecipitation followed by sequencing (ChIPseq). These unbiased genome-wide examinations have revealed novel targets and functions of
p53, at least under specific experimental conditions. For example, in mouse embryonic stem cells
(mES cells), p53 associates with differentiation genes at their promoter regions and acts as a
transactivator. However, p53 also binds distal regions of a gene group related to self-renewal and
pluripotency to functionally repress these genes. Therefore, upon stress induced mES cell
differentiation, p53 enhances expression of differentiation genes but represses ES cell-enriched
genes (Li et al., 2012). In another study in primary mouse embryonic fibroblasts (MEFs), a set of
autophagy genes were identified as direct p53 targets, and contributing to p53’s tumor
suppressive function (Kenzelmann Broz et al., 2013).
One key question in the field concerns whether upon different types of stress, p53 is stimulated to
associate with the genome differently and therefore activate distinct gene expression profiles. In
MCF7 breast cancer cells, treatment with nutlin3a (inhibitor of MDM2 and p53 interaction),
RITA (reactivating of p53 and inducing tumor apoptosis), or chemotherapeutic drug 5-FU (5fluorouracil) resulted in similar binding patterns of p53 to its major binding sites, despite different
biological outcomes by these compounds (Nikulenkov et al., 2012). In contrast, other studies
indicate that different stimuli may lead to distinct p53 binding patterns (Akdemir et al., 2014;
Menendez et al., 2013). However, upon careful analysis of all so far published genome-wide p53
binding datasets (unpublished data from Morgan A. Sammons in our laboratory), most of the
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differences observed in previous studies are likely the result of ChIP-seq peak-calling limitations
(peaks: significant regions of enrichment in ChIP-seq experiments). Indeed, when examining the
enrichment levels regardless of peak calling cutoffs, the binding features of p53 under different
treatments are minimally different. In fact, in the study comparing nutlin3a, RITA and 5-FU,
when increasing the peak-calling stringency, the common overlap is also greatly improved into a
core set of binding sites (Nikulenkov et al., 2012), suggesting a common binding program of p53
among various stimuli as well as subtle stimulus-specific deviations that are also more sensitive
to experimental instabilities.
Nonetheless, the transcriptional outcome goes beyond simple p53 binding, indicating more
complex layers of regulation. The local genomic and epigenetic environment may provide one
such mechanism. In a recently published study that I have participated in, we carefully
characterized genome-wide p53 binding and associated it with the genome-wide patterns of a
number of histone modification marks, in primary lung fibroblasts IMR90 treated with nutlin3a
(Sammons et al., 2015). Consistent with most previously known p53 targets, one set of p53
binding sites occur near gene promoter regions (this set constitutes slightly less than one third of
total p53 binding sites), characterized by histone modification features of gene promoter,
including high levels of H3K4me3 and relatively low amount of H3K4me1. Another one third of
binding sties localize relatively farther away from annotated genes and are associated with high
H3K4me1 and low H3K4me3 signals, therefore demarcating gene enhancer features. Of note, the
remaining more than one third total p53 binding events do not seem to harbor specific histone
modification features, at least not H3K4me1 or H3K4me3, yet the binding strength of p53 at
these sites is as strong as that in the previous two groups, and the distance of these binding sites to
nearest genes resembles that of the enhancer-like group. Further analysis revealed that this third
group of binding sites fall into regions of closed chromatin, as assessed by DNase I
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hypersensitivity analysis; whereas the enhancer-like group correlate with more open and DNase I
sensitive genomic regions. Therefore, this last set of p53 binding sites is referred to as “protoenhancers”. Intriguingly, these epigenetically inaccessible “proto-enhancers” in IMR90
fibroblasts may correspond to true gene enhancer regions in other cell types, in particular
epithelial lineage cells, as these regions reflect open accessible chromatin in epithelial cells as
measured by DNase I sensitivity. These findings collectively support the model that the local
chromatin environment largely affects the functional output of p53, and that the differential
establishment of chromatin features confers another layer of cell type specific and potentially
stress signal specific regulation of p53 transcriptional network.

1.4b

Genome-wide binding of mutant p53

Recently, the investigation of mutant p53 genome-wide binding patterns has also started to gain
interest, as accumulating evidence shows that the transactivation domain of mutant p53 is critical
in mediating “gain-of-function” (discussed in more detail above in 1.2b of this chapter).
Comparing ChIP-on-chip and ChIP-seq analyses in Li-Fraumeni Syndrome MDAH087 cells
bearing the p53 R248W mutation, it appears that the p53 R248W mutant binding associates with
the ETS (E26 transformation-specific) family transcription factor motif. This is likely due to
increased binding affinity of the ETS family member ETS2 with mutant p53 than with wild-type
p53 (Do et al., 2012). The genome-wide association with ETS family transcription factor motif is
further confirmed by ectopically expressing mutant p53 R273H in p53 negative H1299 cells
(Vaughan et al., 2014), suggesting different p53 mutations may have similar features in genomewide binding.
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Assessment of mutant p53 genome-wide locations has also been informative to mutant p53 GOF
mechanisms. We have also taken similar approaches and uncovered new pathways underlying
mutant p53, as discussed below in Chapter 4.
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1.5

Hypotheses and objectives

TP53 is the most critical tumor suppressor gene encoding the potent transcription factor p53.
Upon various cellular stress signals, p53 activates a number of downstream target genes and
tumor suppressive pathways. The importance of p53 is also manifested by the fact that it is
altered in more than half of all human cancers, while a large part of the remaining half of all
cancers inactivate other parts of the p53 signaling pathway.
Testicular teratocarcinoma has long been recognized as a type of cancer that rarely bears p53
mutations, even though the mechanism of the absence of p53 mutation selection power remains
elusive. Recent advances in identifying numerous post-translational modifications on p53,
especially repressive p53 methylation marks, have informed new mechanisms to regulate wildtype p53 activity. We hypothesize a repressive role of p53 methylation, specifically at K370me1
and K382me1, in suppressing p53 transcriptional activity in teratocarcinoma. In Chapter 3, we
examine p53 methylation levels in the NTera2 teratocarcinoma cell line, and test the effects of
perturbing p53 methylation on these cancer cells.
On the other hand, it is now well accepted that mutant p53, in particular “hotspot” missense
mutations of p53, can confer selective cancer growth advantage in addition to loss of wild-type
p53 activity. However the mechanism remains poorly understood, therefore impeding specific
therapeutic interventions of tumors bearing GOF p53 mutations. In Chapter 4, we investigate the
genome-wide binding properties of multiple GOF p53 mutants in an unbiased way, and reveal
novel epigenetic pathways targeted by GOF p53. We characterize the functional importance and
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cancer relevance of epigenetic pathways downstream of GOF p53, and infer possibilities of
targeting chromatin regulators in treating cancers with GOF p53 mutations.
In addition, Chapter 2 describes all materials and methods implemented this dissertation. Chapter
5 briefly summarizes both studies and discusses future directions in detail.
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Figure 1.1

Figure 1.1 | p53 structural domains

(Residue numbers from amino-terminus to carboxyl-terminus)

- 24 -

Figure 1.2

Figure 1.2 | Downstream pathways of p53
Upon various stress signals, p53 can activate one, or multiple downstream pathways that
collectively contribute to tumor suppression.

- 25 -

Figure 1.3

Figure 1.3 | Major mechanisms of mutant p53 “gain-of-function”
A. Mutant p53 interferes with p63 and/or p73 function to abrogate their tumor suppressive
function.
B. Mutant p53 can be directed by other transcription factors to novel genes and activate
tumorigenesis pathways.
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Figure 1.4

Figure 1.4 | The MLL1 COMPASS complex
Major components of the MLL1 COMPASS complex are shown. Common subunits of all six
COMPASS complexes include RBBP5, ASH2 and WDR5. Others are variable among different
complexes. For example, this MLL1 complex has Menin, LEDGF and others (not shown).
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CHAPTER 2
Materials and methods

This chapter provides information regarding all experimental materials and methods employed in
this dissertation.
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Cell lines
NTera2, MCF7, MDA-MB-175VII, HCC70, BT-549, and MDA-MB-468 cell lines were obtained
from American Type Culture Collection (ATCC) and were cultured in a 37 °C incubator at 20%
oxygen. NTera2 cells were maintained in standard tissue culture medium (DMEM with 10%
FBS, 100 units per ml penicillin and 100 mg per ml streptomycin) supplied with sodium
pyruvate. MCF7, MDA-MB-175VII, HCC70, BT-549, and MDA-MB-468 cells were cultured in
standard tissue culture medium supplied with non-essential amino acids. Li-Fraumeni Syndrome
cell lines MDAH087 and MDAH041 were obtained from Michael A. Tainsky (Wayne State
University, Detroit, MI) as a gift, and were cultured in a 37 °C incubator at 3% oxygen, in
standard tissue culture medium. R172H knock-in mice were generated by Tyler Jacks
(Massachusetts Institute of Technology) and obtained from the NCI Mouse Repository. Primary
MEFs from 13.5-day embryos were generated as previously described (Lee et al., 2010), and
cultured in standard tissue culture medium in a 37 °C incubator at 3% oxygen condition.

NTera2 cell differentiation
NTera2 cells were plated 4 × 10 cells per 10cm plate or 1 × 10 cells per 6cm plate, together
with 10μM retinoic acid. Retinoic acid is refreshed every two days. The differentiation time
course is usually 4 days.

Western blot and antibodies
Cells were lysed in modified RIPA buffer containing 150 mM NaCl, 1% NP-40, 50 mM Tris-Cl,
pH 8.0, and 1% SDS, supplemented with protease inhibitors (Life Technologies, number 78446)
before use. Protein concentration was determined by BCA protein assay (Life Technologies,
number 23227), following which equal amount of proteins were loaded and separated in
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polyacrylamide gels. Proteins were then transferred to nitrocellulose membrane. Antibodies used
in this study were as follows: Smyd2 (abcam, ab108712), Pr-Set7 (abcam, ab3798), Nanog
(abcam 21624), Oct4 (abcam ab19857), p21 (abcam, ab7960), PUMA (Cell Signaling
Technology, number 4976), p53 monoclonal antibody DO-1 (Calbiochem EMD); p53 polyclonal
antibody FL393 (Santa Cruz Biotechnology, sc-6243). Flag (Sigma, M2, F1804), HA (Rockland,
600-401-384), histone H3 (abcam, ab1791), H3K4me1 (abcam, ab8895), H3K4me2 (Active
Motif, 39142), H3K4me3 (abcam, ab8580), H3K9ac (Active Motif, 39137), H3K14ac (Active
Motif, 39616), H3K27ac (abcam, ab4729), H3K36me3 (abcam, ab9050), ETS2 (Santa Cruz
Biotechnology, sc-351), MLL1 (Bethyl Laboratories, A300-086A), MOZ (Novus Biologicals,
21620002), mouse p53 antibody for ChIP experiments (Santa Cruz Biotechnology, sc-1312 (M19)), mouse p53 antibody for western blot analysis (Cell Signaling Technology, number 2524),
RNA polymerase II (abcam, ab817).

Co-immunoprecipitation
Flag tagged ETS2 protein was transfected (Life Technologies, number 11668019) and expressed
in HEK293T cells and then subjected to immunoprecipitation with Flag antibody conjugated
protein G Dynabeads (Life Technologies, number 10004D). Following stringent washes, HA
tagged wild-type p53 or GOF p53 (generated by in vitro translation (Thermo, number 88881))
was added to co-immunoprecipitate with Flag-ETS2 in buffer containing: 20 mM Tris, pH 8.0,
137 mM NaCl, 1 mM MgCl2, 1 mM CaCl2, 1% NP-40, and protease inhibitors. Endogenous coimmunoprecipitation experiments were performed in buffer containing: 20 mM Tris, pH 8.0, 137
mM NaCl, 1 mM MgCl2, 1 mM CaCl2, 1% NP-40, 10% glycerol, with protease and phosphatase
inhibitors, and 12.5 U ml-1 benzonase (Novagen, 70746).
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Peptide competition
Prior to immunoblotting, p53 methylation specific antibodies were pre-incubated with 10ng/ml or
100ng/ml peptide (mono-methylated or unmodified) in 3% BSA in TBST. Peptide corresponding
to K370me1 is based on p53 protein sequence from amino acid 361 to 381, with monomethylation at K370. Peptide corresponding to K382me1 is based on p53 protein sequence from
amino acid 367 to 388, with mono-methylation at K382.

Bacterial expression and GST pulldown
GST-tagged ETS2 constructs were transformed and expressed in BL21-CodonPlus E. coli.
Bacterial lysates were incubated with glutathione beads (Life Technologies, number G2879) at 4
°C for 2h, and washed four times with buffer containing 50mM Tris, pH 7.5, 150 mM NaCl, 1%
Triton, 1 mM DTT, supplemented with 100 mM PMSF. The in vitro translated (Thermo, number
88881) HA tagged wild-type p53 or GOF p53 proteins were pre-cleared with GST at 4 °C for 1 h
and the resulting supernatant was subjected to GST pulldown with GST or GST-ETS2. The
product was then washed and subjected to western blot analysis.

RT-qPCR, ChIP-qPCR and ChIP-sequencing
RNA was isolated from cells using RNeasy kit (Qiagen, number 74106). RNA was then reverse
transcribed to cDNA (Life Technologies, number 4387406), then qPCR was performed for
quantification using standard procedures on a 7900HT Fast-Real-Time PCR platform (ABI).
ChIP was performed as previously described (Shah et al., 2013), with modifications. In brief,
cells were crosslinked in 1% formaldehyde (Thermo, number 28906) in PBS for 10 min at room
temperature. After glycine quenching, cell pellets were collected and lysed as previously
described (Shah et al., 2013), and then subjected to sonication using the Covaris sonicator (S220).
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The supernatant was then diluted in the same sonication buffer but without N-lauroylsarcosine,
and subjected to immunoprecipitation with corresponding antibodies at 4 °C overnight. The beads
were then washed and DNA was reverse-crosslinked and purified. Following ChIP, DNA was
quantified by qPCR using standard procedures on a 7900HT Fast-Real-Time PCR platform
(ABI), or sequencing libraries were prepared using NEBNext Ultra library preparation procedure,
and then sequenced on Illumina Hi-Seq platform at the Next Generation Sequence Core at
University of Pennsylvania, or on Illumina Next-Seq platform in the Epigenetics Program at the
University of Pennsylvania. All qPCR primer sequences used in this dissertation are available in
Table 2.1 and Table 2.2.

Growth curve measurement
200,000 cells were seeded on 950 mm2 surface area (one well of 6-well plate) on day 0. Cell
number was measured every two days with Countess automated cell counter (Life Technologies)
following standard procedures and default parameter settings, after which 200,000 cells were
plated back for the next count. For shRNA-mediated knockdown experiments, cells were seeded
7 days after the initial infection of shRNA-containing lentivirus, during which puromycin
selection was completed and cells were returned to normal growth medium. For small compound
inhibitor treatment experiments, inhibitors or DMSO vehicle control were added on day 0 as cells
were seeded, and refreshed every other day as cells were counted and replated. All short hairpin
sequences used in this dissertation are available in Table 2.3.

Colony-formation assay
After lentiviral infection of shRNA constructs and puromycin selection, 2,000 cells were seeded
per well in 6-well plates. After three weeks, cell colonies were fixed with 1% paraformaldehyde
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and stained with 0.1% crystal violet (for 15 min). For quantification, the crystal violet dye was
released into 10% acetic acid and measured at A590nm (OD590).

Tumor xenograft assay
A total of four male and four female mice (Mus musculus, strain NOD.Cg-Prkdcscid
Il2rgtm1Wjl/SzJ, Jackson Labs (stock number 005557)) between the ages of 38 and 45 days old
were used per treatment for tumour xenograft experiments. All animal experiments described
adhere to policies and practices approved by the University of Pennsylvania Institutional
Biosafety Committee (IBC) and the Institutional Animal Care and Use Committe (IACUC). Cells
were collected after shRNA (MLL1 or non-targeting control) mediated knockdowns. Then 1.5
million cells were injected subcutaneously per mouse. Tumor size was measured by calipers 10
weeks after subcutaneous injection. Tumor size was measured in two dimensions, and tumor
volume was calculated as 0.5 ×

ℎ×

ℎ . All mice were euthanized 20 weeks after

subcutaneous injection. Tumors were then excised and photographed.

ChIP-sequencing and RNA-sequencing analysis
Human cell sequencing reads were aligned to human genome hg18 using Bowtie2 (Langmead
and Salzberg, 2012). For p53 ChIP-seq, peaks were called using HOMER (Salk Institute,
http://homer.salk.edu). For area under the curve analysis, ChIP-seq tags from each cell line were
counted at TSS proximal peaks (200 bp around peak centers) of every cell line (including itself)
as indicated. Heat maps of p53 enrichment across a 5 kb region (±2.5 kb from peak center, bin =
10) in MCF7, MDA-MB-175VII, MDA-MB-468, HCC70, BT-549 cell lines were generated
using HOMER and visualized using JavaTreeView. Sequencing reads from MEFs ChIP-seq
experiments were aligned to the mouse reference genome mm9 using Bowtie2. Strand-specific
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mouse RNA-seq experiments were aligned to the mm9 reference genome and reference
transcriptome. FPKM expression values were counted for each exon and merged into a single
gene model using HOMER.

Motif analysis
To determine associated sequence motifs for wild-type p53 or GOF p53 peaks, all TSS proximal
peaks (filtered to remove peaks overlapping with satellite DNA) were pared down to the central
50 bp and used as input to MEME and the SeqPos utility in Cistrome (central 100 bp as required
by SeqPos). MEME was instructed to search for the top 10 motifs appearing 0 or more times in
each sequence, and SeqPos was run with default parameters.

Gene ontology analysis
GO terms associated with wild-type p53 or GOF p53 binding sites were determined in the
following way. ChIP-seq TSS proximal peaks were associated with the nearest ENSEMBL
transcript and processed using DAVID. The FDR was controlled at 1% and GO terms with fewer
than 5 associated transcripts or a fold-enrichment over the genomic background under fivefold
were discarded.

Intersection with ENCODE transcription factor datasets
Transcription factor peak coordinates (hg18 assembly) were obtained from the ENCODE project
repository (http://www.encodeproject.org) in BED format. TSS proximal p53 ChIP-seq peak
regions were intersected with all transcription factor binding-site data using BEDTools, with
overlap inferred if a minimum of a single base pair was in common.
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The Cancer Genome Atlas (TCGA) analysis
Exome sequencing and RNA sequencing datasets were obtained from TCGA (https://tcgadata.nci.nih.gov/tcga/). Based on p53 mutational status from the exome sequencing data sets, we
grouped tumor samples into: (1) wild type (tumors without detectable p53 mutation); (2) GOF
(tumors with p53 single missense mutation of R175H, R248Q, R248W, R249S or R273H); and
(3) null (tumors with p53 nonsense mutations or frameshift truncations). Tumors with other types
of p53 mutations (other missense mutations, inframe insertion/ deletion, or splicing mutations)
were not included in further analysis, due to an unpredictable effect on the downstream chromatin
regulators. Cancer types that include more than 5% samples in group 2 were included for the
combined analysis, in which RNA expression values were normalized to the wild-type group
median. For individual cancer type analysis, original RNA expression values (normalized read
counts or RPKM values) from TCGA datasets were used.

OICR-9429 WDR5-MLL1 inhibitor
OCIR-9429 was developed using structure-guided medicinal chemistry and peptide displacement
assays starting from “Compound 3” previously reported (Senisterra et al., 2013), as part of the
Chemical Probe Program of the Structural Genomics Consortium. OICR-9429 is highly specific
for WDR5 and was shown to have >100-fold selectivity over 300 other chromatin “reader”
domains, methyltransferases, and other non-epigenetic targets. The details of its structure,
discovery and characterization are described in (Grebien et al., 2015).
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Table 2.1
ChIP-qPCR primers (sequences targeting humam genome unless otherwise denoted)
Sequence
Name
TTTTCCCGAGCAATGCCTC
MLL1 peak F
ACCTGGATAACTGCATGCCC
MLL1 peak R
AGGTCCCTATACTGCCAGCCA
MLL1 down peak F
GGTAGAGGGTGGAGGTGAAGG
MLL1 down peak R
CCAGAGCTGAGTGCAACCTG
MLL1 up peak F
ATTTGGGAAGGAGGGAGAGG
MLL1 up peak R
ATCCCGCCCTCTCGGAG
MLL2 peak F
GCGTGTGCGTAGAACTGCAG
MLL2 peak R
CTATTTCCCCATCCCTGCAG
MLL2 down peak F
TGGGAATCAGCATTGGGATC
MLL2 down peak R
AGATGCCCCAAACTGACACG
MOZ peak F
CGGCTGGAGCTCACTGTCTC
MOZ peak R
TGCAGTGAACTATGATCGCCA
MOZ up peak F
TCTTGCTGTGTCTCTCAGGCTG
MOZ up peak R
GACCAGCAGCAAAATCGGAG
(Mouse) p21 BS F
CCCAGGACTGAACAGACCCA
(Mouse) p21 BS R
ACCTGGATAAGTGCATGCCC
(Mouse) MLL1 peak F
TCTTCCCTGGCGCTGCCGC
(Mouse) MLL1 peak R
TTCCACGAGGCACCAAACA
(Mouse) Hoxa9 TSS F
CAGTCCTTGCAGCTTCCAGTC
(Mouse) Hoxa9 TSS R
CGTGACTAATGTGCAGCTTGC
(Mouse) Hoxa5 TSS F
CCGCTCAGCCCCAGATCTA
(Mouse) Hoxa5 TSS R
TTTCTTGGCCGCCTTCTTCT
(Mouse) Hoxa2 TSS F
CTGCAGCCGCCTGAGTATC
(Mouse) Hoxa2 TSS R
ATGGGATGGATCTCAGCGTC
(Mouse) Hoxb5 TSS F
CAAAGTGGCTGGAGGAGGC
(Mouse) Hoxb5 TSS R
GTCCGACTGCGCACAGG
(Mouse) Hoxb6 TSS F
TTCTGCTCCTCGGTCTCTCC
(Mouse) Hoxb6 TSS R
TCGATCATAAGTCACGAGAGCG
(Mouse) Hoxb9 TSS F
CGAAGGAAACTTGGCTGGAG
(Mouse) Hoxb9 TSS R
GGCTGGTGGCTATTTTGTCC
p21 BS F
CCCCTTCCTCACCTGAAAACA
p21 BS R
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Table 2.2
RT-qPCR primers (sequences targeting humam genome unless otherwise denoted)
Sequence
Name
TCTCACATCCTGCACCAGCA
MLL1 RT F
TTCTTGGCTCGGGAACACAT
MLL1 RT R
GCATTGGTGGTTTCATGGTG
MLL2 RT F
TTTTCGTGCGTGTGTGGG
MLL2 RT R
CTCACACGCAGAGATTGCAAG
MOZ RT F
TGGAAATGTGCCCCTTCACT
MOZ RT R
AGAAGTGCCAACAGGCTTGG
ETS2 RT F
TCACAGTTGGCGGAGTCATG
ETS2 RT R
AATATAGGTGGCCCAGAAGGC
(Mouse) Hoxa5 RT F
GTAGCGAGTGTAGGCCGTCC
(Mouse) Hoxa5 RT R
AATAAAATTTGCGAAGGAAGCG
(Mouse) Hoxb9 RT F
GTTGGTTTGATCCGGCCTC
(Mouse) Hoxb9 RT R
GTCCACCTCACGGACAGACA
(Mouse) Hoxa10 RT F
CATCCTGCGATTCTGAAACCA
(Mouse) Hoxa10 RT R
CGGGCTCATCAACGATAAGC
(Mouse) Mll1 RT F
CAGGCCCAGATGTCAGGTG
(Mouse) Mll1 RT R
AGCGATGGAACTTCGACTTTG
p21 RT F
CGAAGTCACCCTCCAGTGGT
p21 RT R
AGATCAAGCGCCAGAATGGA
Lamin A/C RT F
GTGGGAACCGGTAAGTCAGC
Lamin A/C RT R
CCAGAAAACCTACCAGGGCA
p53 RT F
GAATGCAAGAAGCCCAGACG
p53 RT R
AAATGAATCCCCCCCTTCC
MDM2 F
CACGAAGGGCCCAACATCT
MDM2 R
GTAACCCGTTGAACCCCATT
18S rRNA F
CCATCCAATCGGTAGTAGCG
18S rRNA R
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Table 2.3
shRNA and sgRNA targeted sequences
Sequence
GTCCAGATGAAGCTCCCAGAA (shRNA)
GCTGTGATGAGTCAAGCCTTA (shRNA)
CCAACCATGTCTTTCAAGGAT (shRNA)
TTAAATTAGGATAATACCGCG (shRNA)
CGGGCGTAAACGCTTCGAGAT (shRNA)
CCGACCTATCCTTACCATCAT (shRNA)
GCTCTGTGTTTGAGGACAGTA (shRNA)
CGATATTTCCTGATGTTGCAT (shRNA)
CGCAACAGAATCGCAAACTTA (shRNA)
ACTGAGTTCTCTTCCTGAA (sgRNA)

Name
(Human) p53
(Human) ETS2 #20
(Human) ETS2 #21
(Human and Mouse) MLL1
(Mouse) p53 #54549
(Mouse) p53 #12359
(Human) Smyd2 #70313
(Human) Smyd2 #70314
(Human) Pr-Set7
(Human) Pr-Set7
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CHAPTER 3
Lysine methylation represses wild-type p53 activity
in teratocarcinoma cells

Jiajun Zhu, Arnold J. Levine, and Shelley L. Berger

The text, figures, and legends in this chapter were the work of Jiajun Zhu. Part of this chapter is
still ongoing work towards final publication. Current results are discussed in the Results (3.3)
section, and remaining work underway is detailed in the Discussion (3.4) section.
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3.1

Abstract

Testicular teratocarcinoma cells retain high expression levels of wild-type p53, yet the
transcriptional activity of p53 is kept repressed compared to other cancer cells bearing wild-type
p53. Here we report that p53 in the teratocarcinoma cell line NTera2 is subject to lysine
methylation at the carboxyl-terminus, post-translational modifications that are previously known
to repress p53 transcriptional activity. We show that reduction of the cognate methyltransferases
reactivates p53 activity and promotes the differentiation phenotype of NTera2 cells. Our results
provide one of the first lines of evidence that lysine methylation functions to suppress p53
activity in cancer cells, and suggest new possibilities of targeting testicular teratocarcinoma.
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3.2

Introduction

Teratocarcinoma consists of embryonal carcinoma and various layers of differentiated cells. It is
one type of germ cell tumor, and therefore indicates true pluripotent cells have become cancerous.
Teratocarcinoma has been historically linked to p53 because it is a cancer type known to express
high levels of p53. In fact, when p53 was initially misinterpreted as an oncogenic tumor antigen,
teratocarcinoma served as an illustration of cancer with elevated oncogene expression (Bartkova
et al., 1991; Chandrasekaran et al., 1982; Oren et al., 1982; Reich et al., 1983). It is now well
recognized that p53 is the most potent tumor suppressor and yet p53 is rarely mutated in
teratocarcinoma (Lutzker and Levine, 1996). It turns out that p53 is transcriptionally
compromised in teratocarcinoma despite its high expression level. Therefore there does not seem
to be selection power for p53 mutations. However, upon DNA damage or retinoic acid (RA)
induced differentiation of the embryonal carcinoma component, p53 is rapidly activated (Curtin
et al., 2001; Lutzker and Levine, 1996), suggesting an otherwise suppressed basal state that can
be switched on or overcome by stress signals. Although several explanations have been proposed
indicating a repressive domain of p53 that acts in trans (Curtin and Spinella, 2005), or micro
RNAs that function to interfere with p53 downstream pathways (Voorhoeve et al., 2006), the
mechanism of p53 repression in teratocarcinoma remains largely elusive.
A number of post-translational modifications have been identified to occur on p53, providing an
additional layer of transcriptional modulation. These modifications can either be activating or
repressing to p53 transcriptional activity (Berger, 2010; Dai and Gu, 2010). Among them,
methylation of carboxyl-terminal lysines, in particular, mono-methylation at K370 (K370me1,
catalyzed by Smyd2) and mono-methylation at K382 (K382me1, catalyzed by Pr-Set7) have been
associated with p53 repression (Huang et al., 2006; Shi et al., 2007). A recent study using single
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cell imaging revealed an important physiological role of p53 methylation in response to transient
genomic stress such as DNA replication. p53 exhibits dynamic pulses upon intrinsic damages, but
lysine methylation keeps p53 functionally compromised and prevents it from activating the cellcycle arrest pathway unnecessarily (Loewer et al., 2010). This mode of regulation demonstrates
the importance of p53 methylation and may infer other physiological and pathological roles of
p53 methylation. We hypothesized that lysine methylation is exploited by teratocarcinoma cancer
cells as a mechanism to suppress wild-type p53 activity.
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3.3

Results

3.3a

NTera2 exhibits high protein levels of Smyd2 and Pr-Set7

We first performed western blot analyses in the teratocarcinoma cell line NTera2, and compared
protein levels in parallel with those in multiple other cell lines bearing wild-type p53. As
previously noted, the teratocarcinoma cell line NTera2 has a higher protein level of p53 than that
in most other wild-type p53 cell lines we examined, including a primary lung fibroblast line
IMR90 and cancer cell lines U2OS, MCF7, A549 and A498 from various tissues of origin (with
the exception of A498 cells having comparable amount of p53 expression level). However, the
expression levels of canonical p53 targets, including p21 and PUMA, are the lowest in NTera2
when compared with these other cell lines (Figure 3.1). This observation is consistent with
previous reports, and again indicates high levels but transcriptionally compromised wild-type p53
in teratocarcinoma cells.
We then examined protein levels of the p53 methyltransferases Smyd2 and Pr-Set7 (correspond
to K370me1 and K382me1, respectively) in NTera2 cells. Interestingly, among all these cell lines
we examined, NTera2 cells appear to have the highest expression level of Pr-Set7 (Figure 3.1).
Similarly, the amount of Smyd2 protein in NTera2 cells is higher than that in most other cell
lines, except for a comparable amount in A498 cells (Figure 3.1). Together, elevated p53
methyltransferases protein levels in NTera2 cells suggest a potential role of corresponding p53
methylation in regulating p53 activity.
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3.3b

Characterization of p53 methylation specific antibodies

In order to examine p53 methylation in the teratocarcinoma cell line NTera2, we characterized
the specificity of the antibodies against p53K370me1 and p53K382me1. We first tested the
antibodies by overexpressing Flag tagged wild-type p53 or p53 with lysine residues mutated to
arginine at K370 or K382. After ectopic expression in HEK293T cells and immunoprecipitation
by Flag antibody, only wild-type p53, but not the mutant forms K370A or K370R, was
recognized by the p53 K370me1 antibody (Figure 3.2A). Notably, ectopically expressed wildtype p53, but not the mutants, were subject to K370 mono-methylation by endogenous Smyd2 in
HEK293T cells. Moreover, when Smyd2 was transfected and expressed together with Flag tagged
p53, the p53K370me1 signal was further enhanced against wild-type p53, but neither of the
mutant forms (Figure 3.2A). These results indicate that the p53K370me1 antibody does not crossreact with p53 that has lost the K370 residue. Likewise, by performing a similar experiment using
wild-type p53 or the p53 K382R mutant and an antibody against p53K382me1, we also verified
the specificity of this K382 mono-mehylation antibody (Figure 3.2B).
To further demonstrate the specificity and to test the reactivity of the methylation antibodies
against methylated products over unmodified counterparts, we performed the following peptide
competition experiment. Flag tagged p53 was ectopically expressed in HEK293T cells and then
immunoprecipitated as described above. Wild-type p53 was subject to methylation by
endogenous enzymes whereas the lysine to arginine mutant form was not. Prior to
immunoblotting, the p53K370me1 or p53K381me1 antibody was pre-incubated with peptide
corresponding to p53 amino acid sequences bearing K370me1 or K382me1, respectively. Indeed,
pre-incubation of the antibody with mono-methylated p53 peptide resulted in a decrease of
immunoblotting signal compared to when the antibody was pre-incubated with the unmodified
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counterpart (Figure 3.3A and 3.3B). In addition, a larger decrease in the signal was observed
when the peptide concentration was increased (Figure 3.3A and 3.3B). These results again
indicate that the antibodies against p53K370me1 and p53K382me1 specifically recognize
methylated p53 but have much less reactivity with the unmodified p53 protein.

3.3c

p53 is mono-methylated at K370 and K382 in NTera2 cells

Given the elevated protein levels of Smyd2 and Pr-Set7 in NTera2 cells, we next examined
whether p53 is correspondingly mono-methylated at K370 and K382. We separated the nuclear
fraction from the cytosolic fraction of NTera2 cells, and found p53 is predominantly in the
nuclear part (Figure 3.4A), consistent with previous reports (Lutzker and Levine, 1996). We then
immunoprecipitated total p53 and detected both K370me1 and K382me1 signals in the nuclear
fraction (Figure 3.4B). In addition, we decreased the protein level of Smyd2 in NTera2 cells by
short-hairpin RNA (shRNA) mediated gene knockdown, and observed a concomitant reduction of
p53 K370me1 signal (Figure 3.4C). Together, these results support the hypothesis that p53 is
methylated in NTera2 cells, and that p53 methylation is dependent upon the methyltransferase
protein level.

3.3d

Smyd2 and Pr-Set7 knockdown activate p53 transcription activity and

promote a differentiation feature of NTera2 cells
To investigate the functional importance of methylation to p53 transcription activity, we
examined how decreasing the level of p53 methyltransferases affects the expression of p53
downstream targets. Reduction of Smyd2 protein level by two independent shRNA constructs
both resulted in increased expression of canonical p53 target genes p21 and PUMA (Figure
3.5A), indicative of enhanced p53 transcription activity. Meanwhile, when Smyd2 level was
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reduced, we observed decreases in expression of pluripotent genes Nanog and Oct4 (gene names
NANOG and POU5F1, respectively), suggesting a precocious lost of cell stemness that is
consistent with the increased p53 activity (Figure 3.5A). Similarly, we also tested the effect of PrSet7 knockdown by shRNA, and observed increased p21 expression and decreased Nanog protein
level (Figure 3.5B). To further demonstrate the role of Pr-Set7 and to rule out off-target effects
one single shRNA construct may have, we utilized the CRISPR/Cas9 system (Cong et al., 2013)
to achieve genome editing and gene “knockdown” at a cell population level (gene knockout in a
subpopulation of the entire pool of cells). Along with the reduction of Pr-Set7 at the average
level, p21 was also elevated and Nanog level was slightly decreased when compared a control
small guide RNA (sgRNA) targeting a silent gene PRM2 (Figure 3.5C). The results showed
consistency with the shRNA mediated knockdown experiment, and further supported the role of
Pr-Set7 in p53 suppression, which may in turn contribute to sustain the pluripotent state of
NTera2 cells.
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3.4

Discussion

These results provide evidence that the teratocarcinoma cell line NTera2 expresses high levels of
the p53 methyltransferases Smyd2 and Pr-Set7, when compared to other cell lines bearing wildtype p53. In NTera2 cells, Smyd2 and Pr-Set7 contribute to mono-methylation of p53 at K370
and K382, respectively. Reduction of Smyd2 or Pr-Set7 results in increased expression of p53
target genes p21 and PUMA, whereas levels of pluripotent marker genes Nanog and Oct4 are
lowered. Collectively, these results support the hypothesis that carboxyl-terminal lysine
methylation suppresses p53 activity, and contributes to the pluripotent status of teratocacinoma
cells.
Below we discuss additional approaches that can add direct support to the paradigm, and even
further extensions of this hypothesis are detailed in Chapter 5.

3.4a

Methylation-deficient p53 mutants

While results from the Smyd2 and Pr-Set7 knockdown experiments are in line with the
suppressive role of p53 methylation, the effect of Smyd2 and Pr-Set7 reduction on p53 target
gene and pluripotency gene expression may be caused by mechanisms other than p53 methylation
level changes. To acquire further evidence of a major role resulting from p53 methylation, the
following experiment is proposed taking advantage of the K370R and K382R mutations on p53
that cannot be methylated. Using the CRISPR/Cas9 genome editing system, we have generated a
population of NTera2 cells that have non-detectable p53 protein levels (indicating most cells in
the population are effectively p53 gene knockout). Correspondingly, p21 and PUMA levels have
also been greatly reduced (data not shown). To examine the transcriptional activity of wild-type
p53 and p53 with lysine to arginine mutation at K370 or K382, we will ectopically express these
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different forms of p53 in the CRISPR-engineered p53 “deficient” NTera2 cells and compare their
effects on p53 target gene expression as well as the pluripotency genes.
In fact, the differential effect of wild-type and methylation-deficient p53 on target gene
transcription has been previously inferred from experiments in p53-null H1299 cells (Huang et al,
2006). Introducing the K370R mutant form p53 resulted in two-fold more expression of p21 than
that induced by the wild-type form p53, and full activation in the wild-type group is achieve by
additional knockdown of the Smyd2 enzyme (Huang et al, 2006). A larger difference between
methylation-deficient p53 and wild-type p53 on target gene transcription is expected in NTera2
cells, given the hypothesis that p53 methylation serves as a major mechanism of p53 repression.
In addition, the combination of K370R and K382R mutations may synergize to activate p53
transcription activity.
One caveat of this experiment concerns the ectopic expression level of exogenous p53. Ideally,
the K370R and/or K382R mutations can be knocked-in to the endogenous p53 gene locus using
the CRISPR/Cas9 system. However this genetic engineering involves an essential clonal selection
and expansion step where NTera2 cells are easily subject to self-differentiation. Alternatively, we
will titrate the amount of ectopically introduced constructs and achieve close to endogenous p53
expression level.

3.4b

p53 methylation levels between teratocarcinoma cells and other wild-type

p53 cancer cells
Teratocarcinoma is unique in that it always retains a high expression level of wild-type p53 with
compromised transcription activity. We propose lysine methylation on p53 as a mechanism to
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keep p53 activity repressed. Our experimental results are in support of this hypothesis that
NTera2 cells express higher protein levels of the p53 methyltransferases Smyd2 and Pr-Set7
compared with other cell lines bearing wild-type p53. A further comparison can be made directly
assessing p53 methylation levels in NTera2 cells and other wild-type p53 cells. For example,
NTera2 cells express similar amount of p53 protein, but a much higher Pr-Set7 protein level
compared to MCF7 cells and A498 cells. A critical role of p53 methylation in NTera2 cells
should predict a higher level of p53 K382me1 when compared to the other two cell lines.
Moreover, the clinical significance can also be partially assessed by examining patient tumor
samples from The Cancer Genome Atlas (TCGA). Teratocarcinoma represents a subtype of
testicular cancers, which similarly often retain expression of wild-type p53 that is
transcriptionally inactive. Analysis of RNA-sequencing profiles from TCGA and comparison of
p53 methyltransferase levels between testicular cancer and other cancers may further demonstrate
an important repressive function of p53 methylation specifically in testicular cancer.
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Figure 3.1

Figure 3.1 | Western blot analysis and quantification of protein levels between NTera2,
IMR90, U2OS, MCF7, A549 and A498 cells.
Equal amount of total protein was loaded for each cell line. For quantification, protein levels in
the NTera2 cells were set to 1 for each given blot.
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Figure 3.2

Figure 3.2 | The p53K370me1 and p53K382me1 antibodies recognize wild-type p53 (subject
to modifications by endogenous enzymes) but not p53 with K to R mutations.
A and B. HEK293T cells were transfected with indicated expression plasmids and were subject
to Flag immunoprecipitation followed by antibodies against (A) p53K370me1 and (B)
p53K382me1. F-: Flag tagged.
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Figure 3.3

Figure 3.3 | Peptide competition assay for p53K370me1 and p53K382me1 antibodies.
A. Prior to immunoblotting with Flag tagged wild-type p53 or p53K370R, the p53K370me1
antibody was incubated with different concentration of peptide corresponding to p53 amino acid
361-381, mono-methylated at K370 or unmodified.
B. Prior to immunoblotting with Flag tagged wild-type p53 or p53K382R, the p53K382me1
antibody was incubated with different concentration of peptide corresponding to p53 amino acid
367-388, mono-methylated at K382 or unmodified.
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Figure 3.4

Figure 3.4 | p53 is methylated at K370 and K382 in NTera2 cells.
A and B. p53 immunoprecipitation followed by westerns with p53 K370me1 or p53 K382me1
antibodies.
C. p53 K370me1 immunoprecipitation followed by western with p53 upon control (ctrl) or
Smyd2 shRNA knockdown.
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Figure 3.5

Figure 3.5 | Smyd2 and Pr-Set7 knockdown increases p53 target gene expression.
A. Western analysis of NTera2 cells upon Smyd2 reduction by two independent shRNA
constructs mediated knockdown.
B and C. Western analysis of NTera2 cells upon Pr-Set7 reduction by (B) shRNA mediated
knockdown and (C) CRISPR/Cas9 mediated expression decrease.
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CHAPTER 4
Gain-of-function p53 mutants co-opt chromatin pathways
to drive cancer growth

Jiajun Zhu, Morgan A. Sammons, Greg Donahue, Zhixun Dou, Masoud Vedadi,

Matthäus Getlik, Dalia Barsyte-Lovejoy, Rima Al-awar, Bryson W. Katona, Ali Shilatifard,
Jing Huang, Xianxin Hua, Cheryl H. Arrowsmith & Shelley L. Berger
Published in Nature, 2015, 525(7568):206-11.

The text, figures, and legends in this chapter were the work of Jiajun Zhu with the following
exceptions. Morgan A. Sammons performed the heatmap analysis, H4K3me3 ChIP-seq and
RNA-seq analysis in MEFs. Greg Donahue performed the gene ontology analysis.
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4.1

Abstract

TP53 (which encodes p53 protein) is the most frequently mutated gene among all human cancers.
Prevalent p53 missense mutations abrogate its tumor suppressive function and lead to a “gain-offunction” (GOF) that promotes cancer. Here we show that p53 GOF mutants bind to and
upregulate chromatin regulatory genes, including the methyltransferases MLL1 (also known as
KMT2A), MLL2 (also known as KMT2D), and acetyltransferase MOZ (also known as KAT6A or
MYST3), resulting in genome-wide increases of histone methylation and acetylation. Analysis of
The Cancer Genome Atlas shows specific upregulation of MLL1, MLL2, and MOZ in p53 GOF
patient-derived tumors, but not in wild-type p53 or p53 null tumors. Cancer cell proliferation is
markedly lowered by genetic knockdown of MLL1 or by pharmacological inhibition of the MLL1
methyltransferase complex. Our study reveals a novel chromatin mechanism underlying the
progression of tumors with GOF p53, and suggests new possibilities for designing combinatorial
chromatin-based therapies for treating individual cancers driven by prevalent GOF p53 mutations.
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4.2

Introduction

Most mutant forms of p53 are caused by single amino acid substitutions mapping to the DNAbinding domain (Lawrence et al., 2014). These mutations result in expression of full-length p53
protein, but loss of wild-type (WT) tumor suppressive function (Freed-Pastor et al., 2012; Lang et
al., 2004; Olive et al., 2004). The high prevalence of missense substitutions, particularly certain
“hotspot” mutations, suggests a selective advantage during cancer progression. Indeed, these
mutants gain neomorphic oncogenic functions, including altered cancer spectrum (Lang et al.,
2004; Olive et al., 2004), deregulated metabolic pathways (Freed-Pastor et al., 2012; Zhang et al.,
2013), increased metastasis (Subramanian et al., 2015; Weissmueller et al., 2014) and enhanced
chemotherapy resistance (Do et al., 2012). Evidence from recent studies points to one potential
mechanism of GOF p53, functioning through association with other transcription factors and
driving gene transcription in oncogenic pathways, such as the mevalonate pathway (Freed-Pastor
et al., 2012) and etoposide-resistance pathway (Do et al., 2012). A transcriptional mechanism is
further supported by the importance of retaining an intact transactivation domain for oncogenic
GOF p53 function (Freed-Pastor et al., 2012; Scian et al., 2004). Nevertheless, how GOF p53
contributes to major changes of the cancer genome and transcriptome remains to be elucidated
(Garritano et al., 2013; Scian et al., 2004). Altered chromatin pathways have been implicated in
various aspects of cancer (Dawson and Kouzarides, 2012; Tam and Weinberg, 2013), given their
regulation of genome-wide transcription programs (Kouzarides, 2007; Li et al., 2007). However,
to our knowledge, to date there has not been evidence of direct crosstalk between GOF p53
mutants and chromatin regulation.
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4.3

Results

4.3a

Genome-wide binding of mutant p53

To get insights into the regulatory mechanisms of gain-of-function p53 mutants, we carried out
ChIP-seq to determine genome-wide binding locations of both WT p53 and GOF p53 in a panel
of breast cancer cell lines: MCF7 (wild-type p53), MDA-MB-175VII (wild-type p53), HCC70
(p53R248Q), BT-549 (p53R249S), and MDA-MB-468 (p53R273H). Similar number of
sequencing reads were obtained for each cell line, as well as comparable number of identified
ChIP-seq peaks using the same criterion (data not shown).
We first compared the overall binding patterns between WT p53 and GOF p53. By area under the
curve analysis, we found that the binding of p53 to gene-proximal regions (less than 10 kilobases
(kb)) of transcription start sites (TSS) in the two wild-type p53 cell lines strongly resembled each
other, whereas these wild-type p53 peaks were highly dissimilar from the peaks in any of the
GOF p53 mutants. More interestingly, p53 binding patterns in the three GOF p53 cell lines were
similar when compared to each other (Figure 4.1A). This is further confirmed by a heatmap
analysis of all WT p53 and GOF p53 peaks, and assessing their enrichment in each cell lines
(Figure 4.1B). Again, the two wild-type p53 cell lines displayed similar enrichment patterns
between each other, whereas the three GOF p53 cell lines share common p53 binding regions.
In order to investigate the mechanism of GOF p53 binding, we performed motif analysis for TSSproximal peaks of the p53R273H mutant that predicted the E26 transformation-specific (ETS)
motif as the most enriched. This motif is clearly distinct from the wild-type p53 consensus DNAbinding motif. One ETS family member, ETS2, has been shown to consistently associate with
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mutant p53 (Do et al., 2012). Using in vitro expressed p53 proteins and HEK293T expressed Flag
tagged ETS2 protein, we confirmed that ETS2 interacts with various GOF p53 mutants, but
interacts to a much lesser extent with wild-type p53 (Figure 4.2A), as previously noted (Do et al.,
2012). This was also validated with bacterial expressed GST tagged ETS2 and in vitro translated
p53 (Figure 4.2B). Furthermore, co-immunoprecipitation at endogenous protein levels
demonstrated that ETS2 interacts with GOF p53, but not with wild-type p53 (Figure 4.2C and
4.2D). In addition, we analyzed ChIP-seq datasets from the ENCODE project for all transcription
factors (Consortium, 2012; Gertz et al., 2013), and observed that, compared to other transcription
factors, ETS family proteins have significantly higher overlap with GOF p53 TSS-proximal
peaks, but not with wild-type p53 TSS-proximal peaks (Figure 4.3A and 4.3B). Notably, in both
wild-type and GOF p53 cases, RNA polymerase II (Pol II) group has the highest percentage
overlap with p53 peaks, indicative of transcriptional activity. The extent of Pol II overlap is
similar to the ETS group in GOF p53 cells, but much higher than the ETS group in wild-type p53
cells (Figure 4.3A and 4.3B).

4.3b

GOF mutant p53 targets chromatin regulators

To determine specific functional categories, we performed gene ontology (GO) analysis on TSSproximal peaks. As expected, DNA damage response pathways were most enriched in wild-type
p53 targets. In contrast, p53R273H bound to genes related to translation and ribosomal synthesis
(Figure 4.4A), which was reasonable given the rapid growth rate of these cells. We were
particularly intrigued by GOF p53 binding to a group of genes functionally related to histone
methylation (Figure 4.4A). This was seen in UCSC Genome Browser views at MLL1 (KMT2A)
and MLL2 (KMT2D), genes encoding methyltransferases of histone H3 lysine 4 (H3K4) (Figure
4.4B) that are components of alternative forms of the COMPASS complex. The other two GOF
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p53 mutants that we examined, as well as p53R248W from LFS MDAH087 cells, all showed
similar binding at MLL1 and MLL2 (data not shown). UCSC Genome Browser views confirmed
binding of GOF p53 to a gene encoding a common subunit of COMPASS complexes, RBBP5
(data not shown). In contrast, wild-type p53 did not appear to bind any of these genes, although as
expected it bound promoter regions of its canonical targets, including CDKN1A (which encodes
p21 protein), MDM2 and BBC3 (also known as PUMA) (Figure 4.4B and data not shown). We
then analyzed a large set of 600 chromatin regulators for potential GOF p53 binding, and found
an additional group of chromatin regulatory genes that showed peak enrichment. Of particular
interest among these was MOZ (KAT6A), a histone acetyltransferase, and UCSC Genome
Browser views confirmed the presence of GOF p53 but not wild-type p53 (Figure 4.4B).
Using ChIP-quantitative PCR (ChIP-qPCR), we validated the binding of GOF p53 to MLL1,
MLL2, and MOZ genes, but not adjacently upstream or downstream of the peak regions (Figure
4.5A, 4.5B and 4.5C). Moreover, we confirmed GOF p53 binding to all other targets in the
“histone methylation” GO category (RBBP5, OGT and PPP1CC), and to a few additional
chromatin factors (including SMARCD2 and DCAF10), in all three GOF p53 cell lines (data not
shown). We verified the ChIP-qPCR results with a second p53 polyclonal antibody, FL393
(Figure 4.5D). In parallel experiments with both p53 antibodies, wild-type p53 showed binding to
the CDKN1A and MDM2 canonical binding sites, but not to any of the GOF p53 targets tested
(Figure 4.5E). We also examined a pancreatic cancer cell line, PANC-1 (p53R273H), and
observed a similar binding pattern (Figure 4.5F), suggesting a general phenomenon in various
cancer types.
Furthermore, the ChIP-qPCR signal of GOF p53 was attenuated upon p53 knockdown (Figure
4.6A). Knockdown of ETS2 also led to reduced binding of GOF p53 over MLL1 and MOZ, and to
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a lesser extent, over the MLL2 peak region (Figure 4.6B). To test the association of GOF p53 near
Mll1 in a non-tumor background, we performed ChIP-qPCR in primary mouse embryonic
fibroblasts (MEFs) with GOF p53 or wild-type p53, and consistently, mouse GOF p53 showed
significant enrichment over the Mll1 promoter region (Figure 4.6C). As expected, wild-type p53
bound promoter region of Cdkn1a, but not Mll1 (Figure 4.6C).

4.3c GOF p53 regulates MLL, MOZ, and histone modifications
To examine whether GOF p53 is required for expression of the chromatin regulators, we reduced
GOF p53 levels in human cancer cells and found that the mRNA levels of MLL1, MLL2 and MOZ
were also decreased (Figure 4.7A); whereas no change was detected when the level of wild-type
p53 was reduced (data not shown). MLL1 protein levels were also decreased in the GOF p53
knockdown (Figure 4.7B), but not by wild-type p53 knockdown (data not shown), as was also
observed for MOZ protein levels (Figure 4.7C). Reduction of ETS2 levels led to decreased
expression of MLL1 and MOZ, and to a lesser extent, MLL2 (Figure 4.8A and 4.8B), which was
in accordance with the relative binding changes of GOF p53 to these genes (Figure 4.6B). We
verified the ETS2 knockdown result in another GOF p53 cell line, BT-549, and detected similarly
decreased expression of MLL1 and MOZ, and to a lesser extent, MLL2 (Figure 4.8C and 4.8D).
We performed Pol II ChIP-qPCR and observed concomitantly decreased Pol II occupancy
specifically over MLL1, MLL2, and MOZ TSS regions upon ETS2 knockdown (Figure 4.8E). We
examined the importance of another ETS family member, ETS1. By contrast, ETS1 knockdown
had no effect on the expression of MLL1, MLL2 or MOZ, nor did it alter GOF p53 or Pol II
binding (data not shown). As ETS family proteins consist of 28 members (Hollenhorst et al.,
2011), it is likely that additional ETS protein(s) other than ETS1 may be involved. Nevertheless,
our observations are consistent with previous studies showing that ETS2, but not ETS1, is
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important in mediating GOF p53 function (Do et al., 2012; Xiong et al., 2014).
The regulation of histone-modifying enzymes led to investigation of the cognate histone posttranslational modifications (PTMs). We observed a global decrease in histone H3 lysine 9
acetylation (H3K9ac, catalyzed by MOZ (Voss et al., 2009)) in response to knockdown of GOF
p53, whereas other histone acetylation marks did not show notable changes (Figure 4.9 and data
not shown). The reduction of H3K9ac was also observed when the level of MOZ itself was
decreased by short hairpin RNA (shRNA) (data not shown). In contrast, H3K4 tri-methylation
and H3K4 mono-methylation (H3K4me3 and H3K4me1, catalyzed by MLL1 and MLL2,
respectively (Shilatifard, 2012)) showed only a slight global reduction upon GOF p53 knockdown
(Figure 4.9). This is reasonable, however, given that H3K4 is methylated by six members of the
COMPASS complexes (Shilatifard, 2012), and previous studies showed that inhibiting or
knocking one of them out did not substantially change global H3K4 methylation (Cao et al.,
2014; Wang et al., 2009).
We further validated the regulation of Mll1, Mll2, and Moz by GOF p53 in the knock-in MEFs.
We found significantly higher expression of these genes in GOF p53 MEFs than in wild-type p53
MEFs or in MEFs derived from p53 (gene Trp53) knockout mice (p53 null MEFs) (Figure 4.10A,
4.10B and data not shown). Furthermore, when GOF p53 was reduced, Mll1 expression was also
lowered (Figure 4.10C), and ectopically expressing GOF p53 in p53 null MEFs enhanced Mll1
expression (data not shown). GOF p53 MEFs also showed higher global level of H3K9ac, and a
slight elevation of H3K4me3, compared with wild-type p53 or p53 null MEFs (Figure 4.11A).
Notably, other histone modifications associated with active gene transcription, including
H3K27ac and H3K36me3, remained at comparable levels (Figure 4.11A). In addition, H3K4me3
or H3K9ac did not change upon knockdown of wild-type p53, even though cell growth was
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increased as expected (data not shown). Together, these data suggest that changes in H3K4me3
and H3K9ac are specific to GOF p53 directly activating MLL1 and MOZ enzymes.
The modest global change in H3K4me3 in the presence of GOF p53 prompted investigation of
local changes in H3K4 methylation. We performed RNA-seq and H3K4me3 ChIP-seq in MEFs
with endogenous wild-type p53 or GOF p53. Compared with the genome-wide average, known
MLL1 target genes (Wang et al., 2009) were more highly expressed and displayed higher
H3K4me3 enrichment in GOF p53 MEFs (Figure 4.11B). For example, we observed increased
H3K4me3 level and RNA expression within the Hoxa gene cluster (Figure 4.11C and 4.11D), a
well-studied target of MLL1 and commonly upregulated in leukaemia (Milne et al., 2002;
Nakamura et al., 2002). Conversely, wild-type p53 targets, such as Cdkn1a, showed decreased
RNA expression and TSS-associated H3K4me3 in GOF p53 MEFs (data not shown). Notably,
H3K4me3 enrichment at the TSS of genes in GOF p53 MEFs was slightly, but significantly
higher at a genome-wide level than in wild-type p53 MEFs (Figure 4.11E), consistent with the
slight global increase of H3K4me3 (Figure 4.11A). We validated the H3K4me3 ChIP-seq and
RNA-seq results by ChIP-qPCR and RT-qPCR, respectively, observing significantly higher
H3K4me3 enrichment in GOF p53 MEFs, and higher expression of Hox genes, than in wild-type
p53 or p53 null MEFs (Figure 4.11F and 4.11G).

4.3d MLL1 is essential for cancer phenotype of GOF p53
Previous studies have revealed that cells expressing GOF p53 rely on it for cell growth and
survival (Alexandrova et al., 2015; Lim et al., 2009). GOF p53 knockdown in cancer cells led to a
strong decrease in cell proliferation (Figure 4.12A). By contrast, lowering of wild-type p53 levels
resulted in elevated growth (Figure 4.12B). To investigate the function of GOF p53 driving
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chromatin regulators, we carried out the same time course, and found that the reduction of MLL1
or MLL2 in GOF p53 cancer cells led to a striking loss of cell growth (Figure 4.12C),
phenocopying the knockdown of GOF p53 itself. By contrast, knockdown of MLL1 or MLL2 had
a minimal effect on wild-type p53 cancer cells (Figure 4.12D).
We addressed the importance of this pathway to tumor-relevant phenotypes, first by examining
the ability of cancer cells to form colonies. Reduction of MLL1 led to a decreased colony
formation ability of MDA-MB-468 cells (p53R273H) (Figure 4.13A), but had little effect on the
colony formation efficiency of MCF7 cells (wild-type p53) (Figure 4.13B). Similar results were
observed in breast cancer cells BT-549 (p53R249S) and pancreatic cancer cells PANC-1
(p53R273H) (data not shown). We further confirmed the tumor formation phenotype in
anchorage-independent growth assays in soft agar, showing that decreasing MLL1 specifically
reduced the growth and colony size of GOF p53 cancer cells, but not wild-type p53 cancer cells
(data not shown). We also investigated tumor growth on NOD-scid-gamma (NSG)
immunodeficient mice. Knockdown of MLL1 led to strongly reduced tumor formation ability in
GOF p53 cells, as compared to GOF p53 cells with a non-targeting scrambled control knockdown
(Figure 4.13C and 4.13E). In contrast, MLL1 knockdown did not alter the tumour formation
ability of wild- type p53 cancer cells (Figure 4.13D and 4.13E), again supporting a specific role
for MLL1 in cancers with GOF p53, but not wild-type p53.
To further explore a critical role that these chromatin regulators may play in supporting growth of
GOF p53 cells, and to rule out possible confounding factors in established cancer cell lines, we
performed Mll1 knockdown in the primary MEFs with knock-in GOF p53. Consistently, MLL1
reduction resulted in decreased proliferation of GOF p53 MEFs (Figure 4.14A). Importantly, reexpression of MLL1 in GOF p53 MEFs with p53 knockdown partially rescued the growth defects
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(Figure 4.14B and 4.14C); partial rescue probably results from GOF p53 driving expression of
multiple downstream targets, as described above. These results strongly indicate a direct role of
MLL1, functioning downstream of GOF p53 in maintaining proliferation of GOF p53 cells. We
also performed MLL1 knockdown in human non-cancer LFS cells – MDAH087 (p53R248W) and
MDAH041 (p53 null (Zhu et al., 2001)). Similar to the results obtained in cancer cells and in
MEFs, MLL1 knockdown reduced the growth rate of GOF p53 LFS cells (Figure 4.15A), again
phenocopying the knockdown of GOF p53 itself (Figure 4.15B), but did not reduce the growth of
either p53 null LFS cells (Figure 4.15C), nor primary non-cancer cells with wild-type p53
(IMR90 lung fibroblasts, Figure 4.15D). Re-expression of MLL1 again partially rescued the
growth reduction by GOF p53 knockdown in LFS cells (Figure 4.15E). In addition, MLL2
knockdown also decreased GOF p53 LFS cell proliferation, but not p53 null LFS cells (data not
shown).

4.3e COMPASS inhibitors reduce GOF p53 cell growth
Chromatin regulators have emerged as promising targets of small molecule compounds in various
human diseases including cancer (Dawson and Kouzarides, 2012; Dawson et al., 2012). Menin is
a scaffold protein of the COMPASS complex, directly interacting with the amino-terminal of
MLL1 (Caslini et al., 2007; Huang et al., 2012; Yokoyama et al., 2004), and is crucial for MLL1
activity and for maintenance of a subtype of leukaemia (Thiel et al., 2012; Yokoyama et al.,
2005). We treated both GOF p53 and p53 null LFS cells with the previously reported menin
antagonist, MI-2-2 (Grembecka et al., 2012; Shi et al., 2012). In agreement with the MLL1
genetic knockdown experiments, MI-2-2 showed a dose-dependent inhibition of GOF p53 cell
growth (Figure 4.16A), but had very little effect on p53 null cells (Figure 4.16B).
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Recently, inhibition of MLL1 function has also been demonstrated by targeting its interaction
with the WDR5 subunit of the COMPASS complex (Karatas et al., 2010; Karatas et al., 2013). As
a second approach to pharmacological inhibition of MLL1 activity, we used OICR-9429, a newly
characterized antagonist of interaction of WDR5 with MLL1 (Grebien et al., 2015). This nonpeptide, drug-like molecule binds to WDR5 in the MLL1 binding site of WDR5 (
28

= 93 ±

), and disrupts the assembly of the WDR5/MLL1/ RbBP5 complex in cells with half-

maximum inhibitory concentration (IC50) values below 1 μM (Grebien et al., 2015). In striking
similarity to MI-2-2, we found a dose-dependent inhibition by OICR-9429 of GOF p53 LFS cell
growth (Figure 4.16C), and, again, little effect on p53 null LFS cells (Figure 4.16D). Moreover,
in the genetically controlled MEF cells, we observed similar results, that OICR-9429 specifically
inhibits cell proliferation of GOF p53 MEFs (Figure 4.17A and 4.17B), but not when GOF p53 is
reduced (Figure 4.17A) or in p53 null MEFs (Figure 4.17B). These results provide strong
evidence for a specific growth inhibitory effect of pharmacological drugs in targeting MLL
COMPASS complex activity downstream of GOF p53.

4.3f TCGA analysis
We examined the significance of our findings in the context of human tumor samples, by
analyzing The Cancer Genome Atlas (TCGA). Based on p53 mutational status, we grouped tumor
samples into: (1) wild type (no detectable p53 mutation); (2) GOF (missense mutation of R175H,
R248Q, R248W, R249S or R273H); or (3) p53 null (p53 nonsense mutations or frameshift
truncations). Tumors with other types of p53 mutations (other missense mutations, inframe
insertion/deletion, or splicing mutations) were not included in further analysis, due to an
unpredictable effect on the downstream chromatin regulators. We also focused our analysis on
cancer types that include more than 5% of samples in the group comprising GOF p53. We first
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combined all samples from these cancer types, and observed significantly higher RNA expression
of MLL1, MLL2 and MOZ in GOF p53 tumors, compared to either wild-type p53 or p53 null
tumors (Figure 4.18, top panels). As controls, expression levels of housekeeping genes including
actin (ACTB) and GAPDH are consistent across the three groups (Figure 4.18, middle panels),
whereas expression levels of wild-type p53 targets CDKN1A, MDM2 and PUMA are significantly
higher in the wild-type p53 group than the GOF p53 or p53 null group (Figure 4.18, lower
panels). Next, we examined individual cancer types and observed similar gene expression
patterns as the combination of all cancers (Figure 4.19, 4.20 and data not shown). Notably, given
the heterogeneous population of tumor samples, and the small sample size of certain groups, not
all pairwise comparisons are statistically significant, although the same trends always hold that
GOF p53 tumors express higher levels of MLL1, MLL2, and MOZ than the other two groups. This
is also true with canonical wild-type p53 targets, that is, although not all comparisons are
statistically significant, the wild-type p53 groups always show higher levels of CDKN1A, MDM2
and PUMA than the GOF p53 or p53 null tumor groups.
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4.4

Discussion

Our results indicate that distinct prevalent GOF p53 mutants bind to a common newly identified
group of gene targets genome-wide, to drive expression of genes comprising a chromatin
signature. The GOF p53 mapping occurs immediately associated with ETS motifs, and GOF p53
binds directly to ETS2, indicating that the substitutions in the DNA-binding domain of p53
unleash a latent interaction with ETS family transcription factors, as previously suggested (Do et
al., 2012). Within this chromatin signature gene group targeted by GOF p53, the COMPASS
methyltransferase pathway appears to be particularly well represented, but the new binding
includes other chromatin regulators, such as the acetyltransferase MOZ. We find that expression
of these modifying enzymes is dependent on GOF p53, which in turn elevates activating histone
modifications, including H3K4me3 and H3K9ac. Our evidence points to MLL downstream
pathways as key targets of GOF p53. Thus, as is the case in leukemia bearing translocations of
MLL, MLL pathways may contribute to GOF p53 oncogenic phenotypes and therefore cancer
progression.
Importantly, our findings in both human cancer cells and LFS cells show that GOF p53 cells lose
growth and tumor formation potential with similar timing kinetics upon knockdown of MLL1 as
they do with knockdown of GOF p53. A key comparison – to cancer and LFS cells that express
wild-type p53 or are null for p53 – shows very little response to MLL1 knockdown. Hence, GOF
p53 cells appear particularly dependent for growth on the MLL1 pathway. We provide further
evidence of GOF p53 cell growth dependence on the COMPASS complex, by analyzing cell
sensitivity to two different pharmacological small compound inhibitors. These compounds target
menin or WDR5 interaction with MLL1, and inhibit proliferation of LFS cells and MEFs
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expressing GOF p53 but not p53 null. The effects of the inhibitors are thus analogous to direct
knockdown of MLL1. Hence, we conclude that a large cohort of GOF-p53-driven cancers, the
growth of which was not previously known to be dependent on chromatin pathways, may be
amenable to epigenetic therapeutics.
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Table 4.1

p53 R273H targets GO terms (corresponding to Figure 4.4A)
GO Term
GO:0003735~structural constituent of ribosome
GO:0044445~cytosolic part
GO:0006412~translation
GO:0005840~ribosome
GO:0033279~ribosomal subunit
GO:0022626~cytosolic ribosome
GO:0008135~translation factor activity, nucleic acid binding
GO:0006414~translational elongation
GO:0003743~translation initiation factor activity
GO:0006413~translational initiation
GO:0034708~methyltransferase complex
GO:0035097~histone methyltransferase complex

P-Value
2.83E-04
6.58E-04
1.19E-09
1.05E-06
2.32E-04
1.27E-04
6.02E-06
9.23E-07
3.17E-05
6.19E-06
4.31E-05
4.31E-05
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Figure 4.1

Figure 4.1 | Genome-wide binding patterns comparing WT p53 and GOF p53
A. Area under the curve analysis showing p53 enrichment (ChIP/input) in five cell lines over
TSS-proximal peak regions identified in each cell line. Mann-Whitney U-tests were performed to
compute significance for combined WT and GOF p53 peaks: MCF7 ( = 2.78 × 10 ), MDA-
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MB-175VII ( = 2.15 × 10 ), MDA-MB-468 ( < 2.2 × 10
BT-549 ( = 3.7 × 10 ).

), HCC70 ( = 1.09 × 10 ),

B. Heat maps showing the enrichment of p53 peaks (±2,500 bp around peak center) identified
from each cell line (rows) in all five cell lines (columns) examined by ChIP-seq.
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Figure 4.2

Figure 4.2 | ETS2 interacts with GOF p53 but not WT p53
A. Co-immunoprecipitation of HEK293T cell-expressed Flag-ETS2 with in vitro-expressed GFP
or HA-tagged p53, followed by western blot.
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B. GST pulldown of bacterially expressed GST or GST-ETS2 with in vitro translated wild-type
p53 or GOF p53R175H.
C and D. Co-immunoprecipitation at endogenous protein levels of ETS2 and GOF p53R273H
(C) or wild-type p53 (D) in MDA-MB-468 (C) or MCF7 (D) cells.
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Figure 4.3

Figure 4.3 | ETS family ChIP-seq peaks overlapping GOF p53 or WT p53 TSS-proximal
peaks
A and B. Box plots showing overlap of GOF p53 (A) TSS-proximal peaks from MDA-MB-468
cells or wild-type p53 (B) TSS-proximal peaks from MCF7 cells, with ETS family proteins
(blue), all other transcription factors (grey) or Pol II (white) peaks from ENCODE ChIP-seq data
sets. Whiskers on the box plots represent the inter-quartile range. Mann-Whitney U-tests were
performed to compute significance.
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Figure 4.4

Figure 4.4 | GOF p53 mutants target chromatin regulators
A. GO analysis of p53R273H TSS-proximal peaks (statistics are shown in Table 4.1).
B. UCSC Genome Browser views of p53 occupancy over promoter regions of MLL1, MLL2,
MOZ and CDKN1A.
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Figure 4.5
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Figure 4.5 | ChIP-qPCR validation of GOF p53 binding to chromatin regulatory genes
A, B and C. ChIP–qPCR showing p53 (DO-1 antibody) or IgG (mouse) enrichment (ChIP/input)
over MLL1, MLL2 and MOZ peak regions, in MDA-MB-468 (A), BT-549 (B) and HCC70 (C)
cells.
D. ChIP–qPCR showing p53 (FL393 antibody) or IgG (rabbit) enrichment (ChIP/input) over
MLL1, MLL2 and MOZ peak regions in MDA-MB-468 cells.
E. ChIP–qPCR showing p53 (DO-1 antibody) or IgG (mouse) enrichment (ChIP/input) over
CDKN1A, MDM2, MLL1, MLL2 and MOZ gene regions in MDA-MB-175VII cells.
F. ChIP–qPCR showing p53 (DO-1 antibody) or IgG (mouse) enrichment (ChIP/input) over
MLL1, MLL2 and MOZ peak regions in PANC-1 cells.

Error bars represent mean ±s.e.m.; n=3; two-tailed Student’s t-test: *P<0.05; **P<0.01;
***P<0.001.
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Figure 4.6

Figure 4.6 | ETS2 mediates GOF p53 binding at chromatin regulatory genes
A and B. ChIP–qPCR showing p53 enrichment changes upon reduction of p53 (A) or ETS2 (B)
by shRNA-mediated knockdown.
C. ChIP–qPCR showing p53 or IgG enrichment in MEFs bearing wild-type p53 or p53R172H.
Error bars represent mean ±s.e.m.; n=3; two-tailed Student’s t-test: *P<0.05; **P<0.01;
***P<0.001.
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Figure 4.7

Figure 4.7 | p53 knockdown decreases expression of MLL1, MLL2 and MOZ
A. RT-qPCR measuring mRNA level changes upon shRNA-mediated p53 knockdown.
B and C. Western blot of MLL1 (B) and MOZ (C) protein level changes upon p53 knockdown.
Error bars represent mean ±s.e.m.; n=3; two-tailed Student’s t-test: *P<0.05; **P<0.01;
***P<0.001.
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Figure 4.8

Figure 4.8 | ETS2 knockdown decreases MLL1, MLL2 and MOZ expression levels
A and B. Protein (A) and mRNA (B) levels of MLL1, MLL2 and MOZ upon ETS2 knockdown in
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MDA-MB-468 cells.
C and D. Protein (C) and mRNA (D) levels of MLL1, MLL2 and MOZ upon ETS2 knockdown in
BT-549 cells.
E. PolII occupancy over MLL1, MLL2 and MOZ promoter regions upon ETS2 knockdown in
MDA-MB-468 cells.

Error bars represent mean ±s.e.m.; n=3; two-tailed Student’s t-test: *P<0.05; **P<0.01;
***P<0.001.
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Figure 4.9

Figure 4.9 | Histone PTM changes upon GOF p53 knockdown
Western blot showing histone modification changes upon GOF p53 knockdown over time.
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Figure 4.10

Figure 4.10 | Mll1 expression levels in MEFs with wild-type p53, GOF p53 or p53null
A. RT–qPCR analysis comparing Mll1 expression levels between MEFs bearing wild-type p53,
GOF p53R172H, and p53 null.
B. Western blot (left) and quantification (right) of endogenous MLL1 protein levels in MEFs with
wild-type p53, p53R172H or p53 null.
C. Western blot indicating MLL1 level changes upon p53 knockdown in MEFs with p53R172H.
Error bars represent mean ±s.e.m.; n=3; two-tailed Student’s t-test: *P<0.05; **P<0.01;
***P<0.001.
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Figure 4.11
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Figure 4.11 | Histone modifications in MEFs bearing wild-type p53, GOF p53 or p53 null
A. Western blot measuring endogenous histone modification levels in MEFs bearing wild-type
p53, p53R172H or p53 null.
B. Box plot analysis of RNA levels (left) and H3 normalized H3K4me3 levels (right) at
previously discovered MLL1 target genes.
C. Overlaid UCSC Genome Browser views of H3K4me3 and RNA levels in MEFs with p53 WT
or R172H, over Hoxa gene cluster.
D. Box plot analysis of RNA levels (left) and H3 normalized H3K4me3 levels (right) at Hoxa
gene cluster.
E. Box plot of H3 normalized H3K4me3 levels over all gene TSSs, from H3K4me3 ChIP-seq in
MEFs with wild-type p53 or GOF p53R172H.
F. ChIP-qPCR showing H3K4me3 enrichment (H3K4me3 ChIP/H3 ChIP) in MEFs with wildtype p53, p53R172H or p53 null.
G. RT-qPCR analysis comparing Hox gene expression levels between MEFs bearing wild-type
p53, GOF p53R172H, and p53 null.
For all bar graphs, two-tailed Student’s t-test; *P<0.05; ** P<0.01; ***P<0.001. Error bars

represent mean ±s.e.m.; n=3. For all box plots, Mann-Whitney U-test; *P<0.05; **P<0.01;
***P<0.001.
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Figure 4.12

Figure 4.12 | Knockdown of MLL reduces growth of GOF p53 but not wild-type p53 cancer
cells
A and B. Growth curve analysis of MDA-MB-468 (A) and MDA-MB-175VII (B) cells with
either non-targeting control shRNA or p53 shRNA knockdown.
C and D. Growth curve analysis of MDA-MB-468 (C) and MDA-MB-175VII (D) cells with nontargeting control shRNA, MLL1 shRNA, or MLL2 shRNA knockdown.
Error bars represent mean ±s.e.m.; n=3.
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Figure 4.13

Figure 4.13 | MLL1 knockdown reduces the tumor phenotype of GOF p53 cancer cells
A and B. Colony formation (left) and quantification (right) in MDA-MB-468 (A) or MCF7 (B)
cells with non-targeting control (Ctrl) or MLL1 knockdown (KD). Two-tailed Student’s t-test;
**P<0.01; NS, P>0.05; n=3.
C and D. Excised xenograft tumors 20 weeks after NSG immunodeficient mice were
subcutaneously injected with MDA-MB-468 (C) or MCF7 (D) cells carrying control or MLL1
knockdown. Two representative images out of four total in each group are shown.
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E. Xenograft tumor volumes measured 10 weeks after initial injection described in C and D.
Palpable tumors at a size below 4 mm3 were recorded as 4 mm3 due to difficulties in
measurement. Zeros indicate that the mouse did not have a palpable tumor. Red horizontal lines
shown as average tumor volume of all four mice in each group. Mann-Whitney U-test;
***P<0.001; NS, P>0.05.
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Figure 4.14

Figure 4.14 | Mll1 knockdown reduces proliferation of MEFs bearing GOF p53R172H
A. Growth curve analysis of GOF p53R172H MEFs with either non-targeting control shRNA or
two different Mll1 shRNA knockdowns.
B. Western blot in p53R172H MEFs with control or p53 knockdown, and vector control (Vec) or
MLL1 overexpression.
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C. Growth curve analysis p53R172H MEFs with control or p53 knockdown, and vector control
(Vec) or MLL1 overexpression.

Error bars represent mean ±s.e.m.; n=3.
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Figure 4.15
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Figure 4.15 | MLL1 knockdown reduces proliferation of GOF p53 Li-Fraumeni Syndrome
cells

A and B. Growth curve analysis of LFS MDAH087 cells upon MLL1 (A) knockdown or p53 (B)
knockdown.
C. Growth curve analysis of LFS MDAH041 cells upon MLL1 knockdown.
D. Western blot analysis of MLL1 level (left) and growth curve analysis (right) of proliferation
upon shRNA-mediated MLL1 knockdown in IMR90 cells.
E. Growth curve analysis of LFS MDAH087 cells with non-targeting control shRNA plus empty
vector, p53 shRNA plus vector, and p53 shRNA plus MLL1 expressing vector.
Error bars represent mean ±s.e.m.; n=3.
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Figure 4.16

Figure 4.16 | COMPASS inhibitors specifically reduce growth of GOF p53 but not p53 null
LFS cells.
A and B. Growth curve analysis of LFS MDAH087 (A) and MDAH041 (B) cells treated with
DMSO, and 10 μM or 20 μM MI-2-2.
C and D. Growth curve analysis of LFS MDAH087 (C) and MDAH041 (D) cells treated with
DMSO, and 2 μM or 4 μM OICR-9429.

Error bars represent mean ±s.e.m.; n=3.
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Figure 4.17

Figure 4.17 | OICR9429 specifically reduces growth of GOF p53 but not p53 null MEFs.
A. Growth analysis of p53R172H MEFs carrying control or p53 knockdown, treated with DMSO
or 4 μM OICR-9429.
B. Growth analysis of p53R172H or p53 null MEFs treated with DMSO or 4 μM OICR-9429.
Two-tailed Student’s t-test; ** P<0.01. Error bars represent mean ±s.e.m.; n=3.
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Figure 4.18

Figure 4.18 | TCGA analysis in combined cancer types
Box plots of TCGA RNA expression profiles in combined tumors with wild-type p53, p53 GOF
or p53 null. Mann-Whitney U-tests were performed to compute significance; NS, P>0.05.
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Figure 4.19

Figure 4.19 | TCGA analysis in brain lower grade glioma
Box plots of TCGA RNA expression profiles in glioma tumors with wild-type p53, p53 GOF or
p53 null. Mann-Whitney U-tests were performed to compute significance; NS, P>0.05.
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Figure 4.20

Figure 4.20 | TCGA analysis in head and neck squamous cell carcinoma
Box plots of TCGA RNA expression profiles in head and neck tumors with wild-type p53, p53
GOF or p53 null. Mann-Whitney U-tests were performed to compute significance; NS, P>0.05.
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CHAPTER 5
Future directions

This chapter summarizes previous studies and provides perspectives into future directions of
Chapter 3 and Chapter 4.
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5.1

Summary

The study of lysine methylation on wild-type p53 provides evidence that post-translational
modifications can modulate p53 activity in the context of cancer. In teratocarcinoma, lysine
methylation (K370me1 and K382me1) likely contributes to the repression of p53 transcriptional
activity at basal state, therefore preventing teratocarcinoma cells from differentiation in the
presence a high level of wild-type p53 protein.
The analysis of “hotspot” mutant p53 genome-wide binding reveals an epigenetic mechanism
underlying the progression of cancers with p53 “gain-of-function” mutations. Mutant p53 binds
to a group of novel genes compromising an epigenetic signature. Chromatin regulators including
MLL1, MLL2 and MOZ are specifically upregulated in tumors bearing p53 “hotspot” mutations,
and are critical in mediating mutant p53 “gain-of-fucntion”.
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5.2

Future directions

5.2a Post-translational modifications of p53 in cancer
During retinoic acid (RA) induced differentiation of teratocarcinoma cells, p53 protein level does
not change but its transcriptional activity is greatly enhanced (Curtin et al., 2001; Lutzker and
Levine, 1996). p53 methylation is likely one mechanism to repress p53 activity in
teratocarcinoma cells at basal undifferentiated state. Therefore, one possibility is that during
differentiation, p53 methylation is reduced, or even switched to activating modifications such as
acetylation. We tested this hypothesis by comparing p53 methylation level before and after RA
induced differentiation of NTera2 cells. While p53 protein level did not change upon RA
treatment, the level of its target gene p21 increased with time (Figure 5.1A and data not shown),
consistent with previous reports (Curtin et al., 2001; Lutzker and Levine, 1996). However, neither
p53 K370me1 nor K382me1 level seems to change upon differentiation (Figure 5.1B and 5.1C).
We also examined p53 acetylation at K382 and did not observe any increase after RA treatment
(Figure 5.1C). Therefore, although p53 methylation contributes to the repression of p53 activity
under basal condition, it appears that other mechanisms induced by differentiation signaling can
overcome this suppression effect and reactivate p53.
Interestingly, we tested p53 Serine 15 phosphorylation (S15phos), another modification marker
that corresponds to activation status of p53, and it showed an increase upon RA induced
differentiation of NTera2 cells (data not shown). Nonetheless, only a few p53 post-translational
modification sites have been examined, and the investigation of p53 methylation in
teratocarcinoma has been restricted to mono-methylation of K370 and K382 due to limited
availability of specific antibodies to other sites. In addition to K370me1 and K382me1, di- 101 -

methylation at K373 by methyltransferases G9A and GLP has also been involved in repression of
p53 activity with implications in cancer (Huang et al., 2010). There are likely other modification
sites yet to be discovered that also negatively regulate p53 transcription activity. Modifications
other than methylation may also alter upon differentiation to regulate p53 activity. Therefore, a
more comprehensive and unbiased approach can be taken to investigate post-translational
modifications of p53 in teratocarcinoma and corresponding changes upon differentiation. For
example, modification status of p53 can be examined by mass spectrometry to infer p53
modification changes at the global level. Alternatively, genome-wide RNA sequencing can be
performed to help identify expression changes of p53 modifying enzymes during teratocarcinoma
cell differentiation. The comparison of gene expression profiles will also reveal changes beyond
p53 post-translational modification pathways, and will suggest key signaling events that can also
contribute to p53 transcriptional activation.

5.2b How does p53 methylation repress p53 activity?
The suppressive role of p53 methylation likely applies to other cancer types and p53 methylation
also has normal physiological functions, however, there has been very little knowledge of how
methylation represses p53. One possible mechanism is that methylation may result in decreased
DNA binding ability of p53, because the carboxyl-terminus of p53 has been previously
implicated in regulation of DNA binding affinity (Luo et al., 2004). To test this, p53 binding
strengths at target genes can be examined by ChIP-qPCR, and changes in p53 methylation levels
can be induced by manipulating methyltransferase expression levels. Alternatively, a more direct
assessment of DNA association affinity can be inferred from in vitro DNA binding assays. It is
now possible to specifically incorporate mono-methylated lysine into a particular site of
bacterially expressed protein, using the expanded genetic code and orthogonal synthetase/tRNA
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pairs (Chin, 2011, 2014). Ideally, p53 mono-methylated at K370 or K382 can be generated
together with the wild-type counterpart, and their affinity to bind DNA sequences compromising
canonical p53 binding sites can be compared.
Another possible mechanism to explain the repressive role of p53 methylation, especially if
methylation does not change the DNA binding ability of p53, is that methylation of p53 may help
to recruit co-factors that are repressive to gene transcription. This scenario would resemble the
case with repressive histone methylation. Identification of these co-factors is therefore critical to
understanding the mechanism of p53 methylation mediated transcription suppression. Approaches
such as mass spectrometry can be taken to examine binding partners of methylated p53 from coimmunoprecipitation of p53 K370me1 or p53 K382me1. Or instead, comparison of the coimmunoprecipitates from wild-type p53, mono-methylated p53 and p53 lysine to arginine
mutations generated from the above mentioned bacterial expression system can also identify
unique interaction factors of methylated p53.
Overall, revealing the mechanism of methylation mediated p53 repression will provide insights
into p53 signaling regulation. The knowledge could also provide therapeutic opportunities to
reactivate wild-type p53 in cancer.

5.2c GOF p53 activates MLL1 – in vivo significance?
We concluded that the MLL1 pathway has a critical role in mediating mutant p53 GOF, by ways
of cell proliferation, colony-formation, as well as tumor xenograft assays. Using genetic
knockdown of the MLL1 enzyme, or pharmacological inhibition of the MLL1 COMPASS
complex, we were able to specifically reduce the growth and tumor phenotype of cancer cells
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bearing GOF p53. In order to further demonstrate the significance in an in vivo context, I propose
the following experiment in a mouse esophageal cancer model.
After chronic exposure (around 16 weeks) to the chemical carcinogen 4-NQO (4-Nitroquinoline
1-oxide) in daily drinking water, mice are prone to developing esophageal tumors that
pathologically resemble the human esophageal cancer (unpublished data, Dr. A. Rustgi lab,
University of Pennsylvania). Gain-of-function p53 mutations have been shown to contribute to a
more aggressive tumor phenotype and worse prognosis in human esophageal cancer (Dent, 2013;
McCabe and Dlamini, 2005; Wong et al., 2013). This is also recapitulated in the 4-NQO mouse
cancer model, with L2-cre driving the expression of p53 R172H (mouse equivalent of human
R175H) specifically in esophagus tissues (unpublished data, Dr. A. Rustgi lab, University of
Pennsylvania).
On the other hand, a new generation of the menin-MLL1 interaction inhibitor, MI-503, has
recently been developed and shown to be effective when orally delivered to mice of MLL1rearranged leukemia models (Borkin et al., 2015). In collaboration with Dr. J. Grembacka lab at
University of Michigan, we have obtained the MI-503 inhibitor. A pilot experiment will be
performed in ex vivo cultured cells isolated from tumors of the 4-NQO cancer model. The effect
of MI-503 on ex vivo cancer cells bearing GOF p53 R172H will be examined and compared with
that of wild-type p53 or p53 null ex vivo cancer cells. Furthermore, we will examine the effect of
MI-503 in vivo by combining it with the 4-NQO treatment. Administration of MI-503 either
together with 4-NQO or after tumorigenesis may also help to dissect the best effect of MLL1
pathway inhibition in early versus late stage in cancer development.
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5.2d Downstream targets of MLL and MOZ in GOF p53 tumors
Another important question remaining to be explored is to investigate genes that are in turn
targeted by MLL1, MLL2 or MOZ in cancers bearing GOF p53. MLL and MOZ may target and
aberrantly activate distinct downstream genes in different cancer types. However, there could also
be a set of common targets that are important in mediating mutant p53 “gain-of-function”.
In an effort to identify and characterize downstream targets of MLL1 in GOF p53 cancer, we
performed H3K4me3 ChIP-seq in the breast cancer cell line MDA-MB-468 (p53 R273H) upon
shRNA-mediated knockdown of p53 versus a non-targeting scrambled control. Genes where
decreases of H3K4me3 occur may reflect targets of MLL1 enzymatic activity. We examined
H3K4me3 changes at a genome-wide level, comparing control and p53 knockdown, and found
that the top 5% decrease of H3K4me3 signal occurs at genes compromising ras/rho signaling
functional categories (unpublished data). This preliminary result suggests a role of growthpromoting ras/rho signaling downstream of GOF p53 and MLL1 pathway. Additional
experiments including examination of MLL1 binding and functional characterization of ras/rho
pathway genes can further test this hypothesis and demonstrate important targets of MLL1
downstream of GOF p53.
To further define genes downstream of GOF p53, I performed analyses of TCGA datasets,
looking for all genes that are significantly upregulated in GOF p53 tumors, compared to wildtype p53 and p53 null tumor samples. This set of differentially expressed genes may contain
downstream targets of the chromatin regulators MLL and MOZ, as well as gene mis-regulations
that are due to pathways independent of MLL or MOZ or secondary effects of GOF p53.
Therefore, a more careful analysis of genes from the list including their expression correlations
- 105 -

with MLL and/or MOZ levels will be even more informative. Again, this analysis can be
complemented with the examination of genome-wide MLL and MOZ binding.

5.2e Other chromatin regulators targeted by GOF p53
In addition to MLL1, MLL2 and MOZ, the GOF p53 ChIP-seq analysis has revealed additional
chromatin genes targeted by mutant p53. These genes include additional components in the
histone methyltransferase functional category (Figure 4.4A), as well as genes in other epigenetic
pathways. I have confirmed the binding of GOF p53 to these genes encoding chromatin
regulators, by performing ChIP-qPCR in multiple cancer cell lines (Figure 5.2).
Interestingly, two of these targets have been functionally associated with MLL1 activity.
Retinoblastoma binding protein 5 (RBBP5) is an essential component of the COMPASS complex
(Krivtsov and Armstrong, 2007; Shilatifard, 2012); whereas SMARCD2 was recently found to be
important in the chromatin-remodeling of MLL1 rearranged leukemia (Cruickshank et al., 2015).
These results further indicate a critical role of the MLL1 pathway, which GOF p53 specifically
activates to drive cancer growth. On the other hand, some genes have also been implicated in
other aspects of cancer. For example, the O-GlcNAcylation Transferase (OGT) has been shown
to promote tumor invasion and regulate metabolic survival signals of cancer cells (Ferrer et al.,
2014; Zhang and Chen, 2015; Zhang et al., 2015a; Zhang et al., 2015b). Examination and further
characterization of these chromatin regulators will reveal a more comprehensive regulatory
network of GOF p53.
The discovery of various chromatin regulators targeted by GOF p53 suggests the important role
of epigenetic pathways in mediating mutant p53 “gain-of-function”. It also provides the
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possibility of designing combinatorial chromatin-based therapy in treating tumors with GOF p53
mutations, in line with the recent concept of personalized precision medicine (Aronson and Rehm,
2015; Biankin et al., 2015; Khoury et al., 2015). Different cancer types, different cancer patients,
or cancers with different GOF p53 mutations may rely on different pathways or various
components of the same pathway. Therefore, a more tailored epigenetic therapy will likely to be
most effective.

5.2f Ribosomal synthesis and protein translation
Even though the “histone methyltransferase complex” functional terms turn out to be the most
enriched category over the genome, many more gene ontology terms are functionally annotated as
“ribosomal synthesis” and “protein translation” (Figure 4.4A). Genome browser views shown in
Figure 5.3 are examples of GOF p53 binding at promoter regions of some of these genes. A full
list of all protein translation related genes targeted by GOF p53 is shown in Table 5.1. Compared
to gene transcription, protein translation regulation has long been an overlooked aspect of cancer
progression, however is now being increasingly appreciated.
Genetically, numerous genes encoding for components of the ribosome and protein translation
machinery, when mutated, have been correlated with increased cancer susceptibility (Ruggero,
2013). For example, a number of genes encoding for translation initiation factors (including but
not limited to eIF3, eIF4G, eIF4E and eIF5A2) are amplified or overexpressed in various types of
cancer. These alterations, mostly overexpression, are associated with advanced tumor stages and
poor prognosis (Doldan et al., 2008a; Doldan et al., 2008b; Nupponen et al., 1999; Saramaki et al.,
2001). On the other hand, genetic mutations of the ribosomal components occur in syndromes
known as the ribosomopathies, which are also highly susceptible to cancer development. One
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form of ribosomophathies, the X-linked dyskeratosis congenital, involves mutations in the DKC1
gene, which encodes a key ribosomal RNA (rRNA) modifying enzyme Dyskerin (Heiss et al.,
1998; Ruggero et al., 2003). It turns out that specific uridine modifications on rRNA are
particularly important for the proper translation of a set of mRNAs including many transcribed
from tumor suppressor genes. Therefore the lack of rRNA modification renders the patients with
impaired tumor suppressive mechanisms (Graber and Holcik, 2007; Komar and Hatzoglou, 2011).
Interestingly, in addition to mutations in ribosome and the protein translation apparatus, many
oncogenic signaling pathways, including PI3K-AKT-mTOR, Ras-MAPK and oncogenic Myc,
have been found to tap into protein translation control to favor cancer growth (Frederickson et al.,
1992; Hannan et al., 2011; Waskiewicz et al., 1999; Zeller et al., 2006).
Given the preliminary data from analyzing ChIP-seq results, it is likely that oncogenic GOF p53
can also directly target genes encoding for protein translation regulators. Further validations are
needed to illustrate the direct activating role of GOF p53 on these gene targets, and to
demonstrate the functional importance of protein translation control in tumors with p53 GOF
mutations. Nonetheless, a paradigm emerges that on one hand, GOF p53 co-opts chromatin
regulators which in turn mediate changes of the epigenome to activate gene transcription; on the
other hand, GOF p53 potentially also upregulates protein synthesis regulators and therefore
enhance the protein translation process. Both arms are likely to contribute to cancer progression
of tumors with GOF p53 mutations.
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5.2g GOF p53 interacts with ETS family proteins
GOF mutations abrogate the ability of p53 to directly bind DNA. However, a large part of the
“gain-of-function” properties are mediated through novel interactions with other transcription
factors and thereby indirectly access DNA and activate tumorigenic target genes. Studying the
mechanisms of GOF p53 interaction with these transcription factors not only is critical to
understanding mutant p53 “gain-of-function”, but also holds promise for therapies in treating
tumors with GOF p53. Targeting the interaction of GOF p53 with these novel partners appears to
be very specific in therapeutic practice, as the interaction does not occur in normal cells with
wild-type p53.
The ETS family protein ETS2 is one such transcription factor that mediates mutant p53 “gain-offunction”. GOF p53 activation of MLL and MOZ is at least partially dependent on the presence
of ETS2 protein. Based on experimental results in this dissertation and previous reports (Do et al,
2012; Xiong et al, 2014), ETS2 is also important in recruiting GOF p53 to many other sites. This
interaction seems to be restricted to GOF p53 as the association of ETS2 with wild-type p53 is
minimal. We are very interested in exploring the detailed mechanism of GOF p53 interacting
with ETS2, and why such mechanism is absent in the wild-type p53 scenario even though only
one amino acid is replaced. We have preliminary results suggesting part of the p53 DNA binding
domain is critical for the interaction. This particular portion in the DNA binding domain may
correspond to a region structurally buried in the wild-type protein but becomes exposed due to
conformational changes introduced in the mutant protein (unpublished data). It is therefore clear
that revealing the binding details between ETS2 and GOF p53 can guide the design of small
peptide or small molecule inhibitors of the interaction, and may ultimately serve as therapeutic
drug against GOF p53 tumors.
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Furthermore, in addition to ETS2, a number of other ETS family proteins are able to bind
multiple GOF p53 proteins to various extents (unpublished data). This begs the question of
whether different ETS proteins, along with other transcription factors, preferentially mediate
distinct pathways of the mutant p53 “gain-of-function”. Since some ETS family members have
tissue-specific expression patterns, it is also possible that differential expression of distinct ETS
proteins can partially explain tissue-specific cancer phenotypes with the same GOF p53 mutation.
Many more aspects of GOF p53 binding to the ETS family factors remain to be understood with
regard to the context specific properties of mutant p53 “gain-of-function”.
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Table 5.1

Ribosomal synthesis and protein translation genes targeted by GOF p53
EIF2D
RPS7
EIF2B3
EIF3G
RPL38
MRPL44
MRPL39
RPL37
EEF1A1
RPL29
EIF3D
RPS20
MTIF2
MRPS23
EIF4A2
TEFM
RPL26
RPL27
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Figure 5.1

Figure 5.1 | NTera2 differentiation and examination of p53 PTMs
A. Western analysis of RA induced NTera2 cell differentiation time course.
B and C. IP-western analysis of p53 PTM changes upon RA induced NTera2 differentiation.
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Figure 5.2

Figure 5.2 | ChIP-qPCR validation of GOF p53 mutants binding to genes encoding
chromatin regulators

A, B and C. ChIP-qPCR analysis of (A) p53 R249S, (B) p53 R248Q and (C) p53 R273H binding
signals at promoter regions (peak), or upstream of promoter regions (up) of OGT, PPP1CC,
RBBP5, SMARCD2, DCAF10. Two-tailed Student’s t-test; *P<0.05; ** P<0.01; ***P<0.001.
Error bars represent mean ±s.e.m.; n=3.
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Figure 5.3

Figure 5.3 | Genome browser track views of GOF p53 (R273H) binding at genes encoding
for protein translation regulators.
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